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ABSTRACT 
 
Cellular Mechanisms of Effects of Sphingosine 1-Phosphate on  
Vascular Endothelial Barrier 
 
Mei Xu 
 
Sphingosine 1-phosphate (S1P), a biologically active lipid, induces a myriad of 
cellular events including enhancement of the endothelial barrier and assembly of 
adherens junction proteins, VE-cadherin and catenins. The over all goal in this set of 
studies was to investigate what cellular mechanisms contribute to S1P-induced 
enhancement of the vascular endothelial barrier. 
Since VE-cadherin contributes to the stabilization of the endothelial barrier, I 
determined in the first study if the rapid, barrier-enhancing activity of S1P requires VE-
cadherin.  Ca2+-dependent, homophilic VE-cadherin binding of endothelial cells, derived 
from human umbilical veins and grown as monolayers, was disrupted with EGTA, an 
antibody to the extracellular domain of VE-cadherin, or gene silencing of VE-cadherin 
with small interfering RNA (siRNA).  All three protocols caused a reduction in the 
immunofluorescent localization of VE-cadherin at intercellular junctions, the separation 
of adjacent cells, and a decrease in basal, endothelial electrical resistance.  In all three 
conditions, S1P rapidly increased endothelial electrical resistance.  These findings 
demonstrate that S1P enhances the endothelial barrier independently of homophilic VE-
cadherin binding.  Junctional localization of VE-cadherin, however, was associated with 
the sustained activity of S1P.  Imaging with phase-contrast and differential interference-
contrast (DIC) optics revealed that S1P induced cell spreading and closure of 
intercellular gaps.  Pretreatment with Latrunculin B, an inhibitor of actin polymerization, 
or Y-27632, a Rho kinase inhibitor, attenuated cell spreading and the rapid increase in 
electrical resistance induced by S1P.  I conclude that S1P rapidly closes intercellular 
gaps, resulting in an increased electrical resistance across endothelial cell monolayers, 
via cell spreading and Rho kinase and independently of VE-cadherin.  
 
Based on the previous observation that S1P increases the localization of 
junctional VE-cadherin as early as 10 min, I determined in the second study what 
cellular mechanisms contributed to this increase. Because VE-cadherin dynamically 
traffics between cell surface and cytoplasmic vesicles, I hypothesized that S1P can 
regulate VE-cadherin trafficking. Immunofluorescence microscopy and a biotinylated 
cell impermeable reagent were used to demonstrate internalized and cell surface VE-
cadherin.  Endocytosis of VE-cadherin was induced by EGTA or VEGF. S1P decreased 
EGTA-induced endocytosis and co-localization of internalized VE-cadherin with EEA 1, 
a marker of early endosomes, and prevented and reversed the effect of VEGF.  S1P 
also increased the recovery of cell surface VE-cadherin after endocytosis by EGTA or 
VEGF and increased the co-localization of internalized VE-cadherin with Rab11, a 
marker of the recycling endosome. Bafilomycin A1, an inhibitor of recycling, and 
microtubule inhibitors, taxol and colchicine, blocked the increase in junctional VE-
cadherin and the sustained increase in endothelial electrical resistance induced by S1P, 
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the latter using the Ca2+-switch protocol.  Bafilomycin A1 also prevented the increase in 
recovery of cell surface VE-cadherin induced by S1P.  When co-treated or post-treated 
with VEGF, S1P blocked or reversed the increased interaction of VE-cadherin with β-
arrestin2, an endocytic adapter protein. I conclude that S1P stabilizes homophilic VE-
cadherin binding by decreasing endocytosis and increasing recycling of VE-cadherin, 
the latter requiring microtubules.    
 
In the third study, I investigated the cellular mechanisms contributing to the 
regulatory effects of S1P on VE-cadherin trafficking. S1P increased co-localization and 
interaction of p120 with VE-cadherin and increased biotinylated, cell surface VE-
cadherin and p120 with or without EGTA pretreatment. In addition, S1P enhanced the 
co-localization of p120 with EGFP-tagged Rab11, a maker of recycling endosomes. 
VEGF decreased the interaction of VE-cadherin with p120, and co-treatment or post-
treatment with S1P blocked or reversed, respectively, this effect of VEGF. Interestingly, 
S1P increased the interaction of p120 with kinesin, a motor protein that moves along 
microtubules to transport vesicles. 
  
In summary, I conclude that S1P enhances the endothelial barrier through 
multiple ways: the rapid increase in endothelial barrier function is independent of VE-
cadherin, but requires Rho kinase and actin cytoskeleton-based cell spreading; 
sustained enhancement of the barrier is related to an increase in junctional VE-cadherin 
on which S1P has a novel effect—regulation of VE-cadherin trafficking, i.e. decreasing 
endocytosis and increasing recycling of VE-cadherin. p120 possibly is involved in this 
novel regulatory effect of S1P. Augmented interaction of p120 with kinesin by S1P may 
facilitate transport of recycling VE-cadherin via microtubules.  
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GLOSSARY 
 
 
S1P    Sphingosine 1-phosphate 
HUVEC   Human umbilical vein endothelial cell 
VE-cadherin   Vascular endothelial cadherin 
EGTA    Ethylene glycol-bis(2-amino-ethylether)- 
              N,N,N’,N’-tetra-acetic acid                                                                            
ECIS    Electric Cell-substrate Impedance Sensing  
ER    Electrical resistance 
E/B    Electrical resistance/basal value  
siRNA    Small interference RNA 
DMSO   Dimethyl sulfoxide  
PBS    Phosphate-buffered saline 
TBS    Tris-buffered saline 
BSA    Bovine serum albumin 
SDS-PAGE   Sodium dodecyl sulfate-polyacrylamide-gel 
                      electrophoresis 
DIC    Differential interference-contrast   
Lat    Latrunculin B 
Y    Y-27632 
E-cadherin   Epithelial cadherin 
BPAEC   Bovine pulmonary arterial endothelial cell 
VEGF    Vascular endothelial growth factor 
Sulfo-NHS-SS-Biotin Sulfosuccinimidyl 2-(biotinamido) ethyl-  
                                  dithioproprionate                               
PMSF    Phenylmethanesulfonyl fluoride 
Baf    Bafilomycin A1 
EEA 1    Early endosome antigen 1 
N-cadherin   Neuronal cadherin 
EGF    Epithelial growth factor 
PDGF    Platelet-drived growth factor 
GPCR    G-protein coupled receptor 
Edg    Endothelial differentiation gene 
p120    p120-catenin 
PKC    Protein kinase C 
ICRAC   Calcium release-activated calcium current 
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GENERAL INTRODUCTION 
 
Endothelia adhere to each other through junctional structures to constitute a selective 
semipermeable barrier. Disruption of vascular barrier integrity leads to increases of fluid, 
solutes and proteins across endothelia, resulting in raised permeability which is linked to 
normal biological processes, such as protein and fluid transport, inflammation, white cell 
emigration, vasogenesis, as well as to many pathological processes, for example, 
cancer metastasis and tumor angiogenesis. Two pathways, paracellular and 
intracellular (vesicular), can account for the increased permeability. However, the 
paracellular pathway is considered main pathway that contributes to the increased 
permeability (45). However, the cellular mechanisms are unclear. Suggested 
mechanisms that regulate the endothelial barrier include alterations in the integrity of 
the junctions, the cytoskeleton, focal adhesions and cellular retraction/contraction and 
relaxation. There are two main intercellular junctions between endothelial cells, tight 
junctions and adherens junctions (5, 6, 16, 31). Distribution of tight junctions varies 
along different segments of the vascular tree; tight junctions are well developed in 
arteries and arterioles, but less organized in veins and postcapillary venules, which are 
the primary sites for the extravasation of proteins and leukocytes (5).  Adherens 
junctions (Figure 1) are formed by trans-membrane adhesion proteins of the cadherin 
family, especially vascular endothelial (VE) cadherin, whose cytoplasmic tail is linked to 
the actin cytoskeleton through β- and α-catenin.  p120 catenin stabilizes VE-cadherin at 
the junctional site by binding to the juxtamembrane domain of VE-cadherin (28, 63). VE-
cadherin consists of an extracellular domain with five homologous Ca2+-binding repeats 
(EC1-EC5) that binds homophilically with VE-cadherin on an adjacent cell. It is known 
that VE-cadherin is related to endothelial cell migration, survival, contact-induced 
growth inhibition, vascular integrity and most notably, angiogenesis (17, 18, 42, 61). 
Targeting the extracellular domain of VE-cadherin by specific antibodies, resulting in the 
inhibition of angiogenesis, tumor growth and metastasis, is being developed as a 
potential tool for cancer therapy (13, 14, 38). Interestingly, the loss of VE-cadherin 
expression is related to a variety of pathologies, e. g. inflammation, angiogenesis and 
endothelial-mesenchymal transdifferentiation (1, 10, 62). Thereby, the regulated 
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changes in VE-cadherin level have important consequences on endothelial function and 
pathophysiology. However, the cellular mechanisms that regulate cell surface 
expression of VE-cadherin are poorly characterized.  
              
 
               
Adherens junctions are extensively investigated and are considered as a primary 
regulated site by many endogenous and exogenous factors. Sphingosine 1-phosphate 
(S1P) is a biologically active lipid growth factor (Figure 2) produced in many cells mainly 
from platelets by the phosphorylation of sphingosine (55, 57), and also from 
erythrocytes in a stimulus-independent manner (27). S1P exists in the circulation from 
nanomolar to micromolar concentration, and its activities are regulated by association 
with HDL (active form) or LDL (inactive form) (4). S1P distributes throughout the whole 
cardiovascular system and plays a role in regulation of vascular tone. It is known that 
S1P can induce a myriad of cellular events, such as cellular locomotion, vascular 
maturation, and angiogenesis, as well as enhance the endothelial barrier (45, 46, 57). 
S1P ligates G-protein coupled receptors, known are at least five S1P receptors of the 
endothelial differentiation gene (Edg) family, and elicits a wide variety of intracellular 
signals. Vascular endothelial cells express predominantly S1P-1 (Edg-1) and S1P-3  
 
     Figure 1. Structure of adherens junctions (see text for details). 
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                     Figure 2. Structure of S1P and its bio-activities. 
 
(Edg-3) receptors (26, 37, 45, 46, 51). S1P induces a rapid and dose-dependent 
increase in vascular endothelial barrier function as recorded by increases in trans-
endothelial monolayer electrical resistance (20). For example, S1P induces a dose-
dependent increase in electrical resistance on bovine pulmonary arterial endothelial cell 
(BPAEC) monolayers and a sustained increase in electrical resistance on human 
umbilical vein endothelial cell (HUVEC) monolayers (Figures 3 and 4). S1P activates a 
number of Rho family GTPases, such as Rac 1, Cdc42 and Rho A (20, 22, 35). S1P-
elicited Rac 1 has been studied more extensively and has been linked to S1P-enhanced 
barrier function (20, 58). However, we found that inhibition of Rho-kinase, a downstream 
target of Rho A, also suppresses the S1P-increased electrical resistance in both human 
and bovine cell lines. Therefore, the role of Rho A in S1P effects needs more study. It is 
known that S1P organizes actin filaments into a strong cortical ring (45) and assembles 
VE-cadherin and β-catenin at adherens junctions (20, 36, 47). How the actin 
cytoskeleton or VE-cadherin contributes to the whole process of S1P effects is still 
unclear. Furthermore, what cellular mechanisms contribute to S1P-assembled 
membrane VE-cadheren have not yet been investigated. S1P and other 
lysophospholipids elevate intracellular calcium and trigger exocytosis in non-endothelial 
and endothelial cells (36, 44, 47). S1P induces the exocytosis of Weibel-Palade bodies, 
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and increases glutamate secretion in hippocampal neurons (29, 44). Possibly, S1P is 
able to regulate exocytosis of internalized proteins.                      
 
 
 
Unpublished from Dr. Fred Minnear 
Figure 3. S1P increases electrical                  Figure 4. S1P increases electrical  
                 resistance of BPAECs                                  resistance of HUVECs. 
                 (see text for details).                                    (see text for details). 
 
 
The cadherin family of proteins consists of epithelial (E)-, placental (P)-, neuronal 
(N)-, muscle (M)-, and VE-cadherin and constitutively traffics between cell surface and 
cytoplasm. Expression of cadherin at the plasma membrane is dynamically regulated by 
cadherin turnover, which involves the processes of endocytosis, degradation, and 
recycling. Cadherin first sorts into early endosomes, then goes through later endosomes 
to be degraded by lysosomes, or recycled back to the cell surface via recycling 
endosomes (Figure 5). Endocytosis of cadherins can be mediated through clathrin-
dependent and clathrin-independent (caveolin-mediated) pathways and has been 
observed during development, during epithelial to mesenchymal transition, and in 
response to growth factors and tumorigenic signals (8, 9, 34, 65). The endocytosis and 
recycling of E-cadherin, a member of the cadherin family expressed mainly on epithelial 
cells, have been studied intensively by Stow et al. (8, 9, 33, 34). They found that 13% of 
E-cadherin traffics dynamically. Depletion of extracellular calcium disrupted cell-cell 
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contacts and induced endocytosis of E-cadherin, and repletion of calcium recovered 
surface E-cadherins, which was inhibited by bafilomycin A1, an inhibitor of recycling 
(34). They suggested that the pool of cell surface E-cadherin is constantly trafficking 
through endocytic and recycling pathways. The trafficking of VE-cadherin may be 
similar to that of E-cadherin. Endocytosis of VE-cadherin is an important regulated 
mechanism that accounts for the amount of cell surface VE-cadherin. Down-regulation 
of VE-cadherin initiates endothelial-mesenchymal transdifferentiation and is related to 
atherogenesis (7, 19). Alexander et al. (2, 34) reported that a decrease in extracellular 
calcium reduced cell surface VE-cadherin and 
 
          Figure 5. Trafficking pathway of E-cadherin (see text for details). 
 
 induced endocytosis of VE-cadherin in which protein kinase C is involved. Gavard and 
Gutkind (21) reported that VEGF induces endocytosis of VE-cadherin through a β-
arrestin2, an adaptor protein for endocytosis, -dependent pathway which may contribute 
to the increased permeability by VEGF. Furthermore, endocytosis of VE-cadherin 
facilitates VEGF receptor2 internalization and its downstream signaling (32). However, 
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the mechanisms related to regulation of trafficking of VE-cadherin are unclear, and 
which endogenous factors that regulate VE-cadherin trafficking have not been 
investigated. Interestingly, S1P at low concentration stabilized the vascular endothelial 
barrier through regulation of N-cadherin trafficking (52), but whether S1P has capacity 
to regulate VE-cadherin trafficking that contributes to S1P-induced enhancement of 
endothelial barrier function is not clear. Our study is designed to investigate the cellular 
mechanisms for the regulation of endothelial barrier function induced by S1P. 
 
 Recently, p120 was reported to play a core function for regulation of VE-
cadherin. p120 catenin, a member of the armadillo family of proteins and originally 
identified as a substrate for Src and other tyrosine kinases, interacts with VE-cadherin 
through its ARM domain and binds to the juxtamembrane domain (3).  Iyer et al. (28) 
reported that the interaction of VE-cadherin with p120 is crucial for stabilization of the 
endothelial barrier, and p120 plays a major role in this stabilization; either a decrease or 
increase in expression level of p120 results in disruption of the endothelial barrier.  Xiao 
et al. (15, 63-65) reported that p120 acts as a set point for cadherin expression in 
mammalian endothelial cells. The loss of p120 causes the internalization of E-cadherin 
and delivery to lysosomes for proteolytic degradation. Contrastingly, over-expression of 
p120 strongly inhibited clathrin-dependent endocytosis of VE-cadherin. Interestingly, 
there is a reported interaction of p120 with kinesin, a motor protein, via a segment of the 
N-terminus of p120 that binds to kinesin heavy chain.  Based on this interaction, p120-
kinesin regulates p120 localization and function, and furthermore facilitates the transport 
of the cadherin-catenin complex to intercellular junctions (12, 67).  However, p120 is not 
necessary for proper delivery of new biosynthesized VE-cadherin to the cell membrane 
(63). One goal of my studies is to investigate whether or not p120 is involved in VE-
cadherin trafficking induced by S1P.   
 
 Rab proteins, a large family of monomeric small GTPases, distribute to distinct 
intracellular compartments, and in their active form, coordinate with their effectors to 
regulate vesicle sorting, transportation, and fusion with membranes (53, 59, 60, 68). As 
mentioned above, cadherin turnover mainly includes endocytosis, recycling, as well as 
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degradation of which, respectively, are related to early endosomes, recycling 
endosomes, and later endosomes and lysosomes. Rab5, works together with its 
effector, EEA1 (early endosome antigen 1) to regulate the transportation of clathrin-
coated-vesicles from the plasma membrane to early endosomes as well as homotypic 
fusion of early endosomes. Rab7 localizes at later endosomes and Rab11 and Rab4 
regulate the recycling process. Papers by Moore and Stow (41, 48) have reported that 
Rab11 works as an intermediate compartment for regulation of recycling of beta2-
adrenergic receptors and the post-Golgi trafficking and exocyotosis of E-cadherin. 
Accordingly, Rab proteins are used as markers for specialization of distinct endosomes. 
Other proteins, such as soluble NSF attachment receptors (SNAREs), Vamp3, etc. also 
work in partnership with the function of Rab GTPases. 
 
 Vascular endothelial growth factor (VEGF), formerly known as a vascular 
permeability factor, is essential for vasculogenesis and angiogenesis through ligating to 
its receptor, VEGFR-2. Dejana and co-workers (32) reported that VEGF induced the 
internalization of VEGFR-2, which was facilitated in the absence of cell surface VE-
cadherin. Furthermore, engaged homophilic binding of VE-cadherin retained VEGFR-2 
at the cell membrane and prevented its internalization into signaling compartments. 
Recently, it was reported that the VEGF-induced increase in vascular permeability is 
related to VEGF-induced endocytosis of VE-cadherin (21, 32). These studies outline the 
following sequence of events: VEGF binds to VEGFR-2 and activates Src which 
activates Rac then p21-activated kinase (PAK), which phosphorylates a highly 
conserved motif within the intracellular tail of VE-cadherin, followed by recruitment of β-
arrestin2 to the serine-phosphorylated VE-cadherin, thereby promoting clathrin-
dependent endocytosis of VE-cadherin. Interestingly, S1P is a vascular barrier 
enhancer. Based on the opposite role of S1P, I hypothesize that S1P is able to 
suppress the VEGF-induced increase in vascular permeability by regulating the 
interaction of β-arrestin2 with VE-cadherin, which in turn modulates the endocytosis of 
VE-cadherin.    
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Protein trafficking transports via actin cytoskeletons or microtubules or both (25, 
49). Microtubules, together with the microtubule-based motor proteins, kinesin and 
dynein, play an essential role in membrane trafficking events involved in endocytosis, 
transcytosis, etc. (25, 39, 40, 43, 50, 66). As aforementioned, p120-kinesin interaction 
facilitates the transport of the cadherin-catenin complex to cell-cell contacts via 
microtubules in living fibroblasts (43). Interestingly, S1P was reported to increase 
polymerization of microtubules and facilitate N-cadherin trafficking along it (52, 66).  
However, if trafficking of VE-cadherin goes through microtubules, it has not been 
characterized. In this dissertation, two types of microtubule inhibitors, taxol (inhibits 
depolymerization) and colchicine (inhibits polymerization), were used to investigate the 
effects of microtubules on VE-cadherin trafficking. 
 
As stated above, S1P enhances endothelial barrier function as assessed as an 
increase in electrical resistance by using Electric Cell-substrate Impedance Sensing 
(ECIS) technology (Figure 6). This patented technique, invented by Drs. Ivar Giaever 
and Charles R. Keese (Applied Biophysics, Inc), is one of the main techniques used in 
my dissertation and now is widely applied to measure, in real time, cell motility, cell 
growth, cell spreading, wound healing and barrier function via constantly monitoring the 
changes in impedance of a small electrode to AC current flow (11, 23, 24, 54, 56).  The 
current flows between a small electrode and a larger counter electrode using normal 
culture medium as the electrolyte. Cells are seeded on a gold-coated small electrode 
(250 µm diameter) in ECIS culture wells. The electrical resistance measured is that of 
those cells. When cells attach to the culture wells, the current flows in the spaces under 
and between the cells, as the cell membranes are essentially insulators.  A constant 
current of 1 μA is supplied by a 1-V, 4,000-Hz alternating current through a 1-MΩ 
resistor. Finally, changes in voltage between the small electrode and the large counter 
are monitored by the lock-in amplifier, stored, and then calculated as resistance by the 
computer. On confluent endothelial monolayers, an increase in electrical resistance 
indicates cell-cell contacts becoming tighter, i. e. enhancing endothelial barrier. In 
contrast, decreased electrical resistance means loosened cell-cell contacts.    
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To study protein trafficking, quantitative measurements of internalized and  
     
          Figure 6. ECIS monitors the resistance between cells (see text for details). 
  
cell surface VE-cadherin are essential.  A biotinylation protocol (Figure 7) was adopted 
to measure internalized and cell surface proteins and has been frequently used by Stow 
et al. in their studies on trafficking of E-cadherin (8, 33, 34).  Sulfo-NHS-SS-biotin is a 
water-soluble, membrane impermeable and cleavable biotin reagent that binds to 
primary amines (lysine) through its NHS ester. Since biotin forms a strong non-covalent 
bond when it interacts with avidin or streptavidin, sulfo-NHS-SS-biotin is good for 
purification and extraction of proteins. For measurement of internalized proteins, 
labeling cell surface proteins with sulfo-NHS-SS-biotin is the first step, followed by 
designated treatments to induce endocytosis. Glutathione disrupts S-S bonds in sulfo-
NHS-SS-biotin and removes biotin from the cell surface. Internalized proteins resistant 
to the glutathione wash and still bound to sulfo-NHS-SS-biotin are collected by 
streptavidin beads. However, the measurement of cell surface proteins is somewhat 
different. After treatments, whole cell surface proteins are labeled with sulfo-NHS-SS-
biotin and then collected by streptavidin. Comparing these two methods, the glutathione 
wash is the pivotal step.      
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In summary, the cellular mechanisms of the effects of S1P on endothelial barrier 
function were investigated through measurements of changes in endothelial electrical 
resistance, function of homophilic VE-cadherin binding, junctional localization of VE-
cadherin, cell spreading, interaction of VE-cadherin with other proteins, and trafficking of 
VE-cadherin.  
                                                                                                               
                         
                                        
                          Figure 7. Biotinylation protocol (see text for details). 
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OBJECTIVES 
 
Endothelia lining the inner surface of blood vessels constitute a selective 
semipermeable barrier. Changes of barrier integrity are linked to many physiological 
and pathological processes.  For example, disruption of the vascular barrier by 
inflammatory stimuli increases vascular permeability to fluid and solutes, which can 
result in edema (30). Angiogenesis also requires physiological changes of the 
endothelial barrier (6, 31). The cellular mechanisms that regulate the endothelial barrier 
are not completely clear and may involve a number of cellular processes. Adherens 
junctions containing vascular endothelial (VE)-cadherin, other cadherins and catenins 
(α, β, γ and p120) have been studied extensively and have been considered as primary 
regulated sites by various endogenous and exogenous factors. Calcium-dependent VE-
cadherin mediates cell-cell contacts and plays an essential role in stabilization of the 
vascular barrier. It has been recognized that sphingosine 1-phosphate (S1P), a 
biologically active lipid released mainly by active platelets, enhances barrier function as 
measured by an increase in trans-endothelial electrical resistance (20), and increases 
the localization of VE-cadherin and β-catenin at the adherens junctions (36, 46). 
However, the cellular mechanisms that contribute to S1P effects on endothelial barrier 
function, especially on regulating VE-cadherin, are not fully clear. 
 
The goal of my research is to identify what cellular mechanisms contribute to the 
S1P-induced enhancement of barrier function. 
 
Study 1. To determine if VE-cadherin is involved in the S1P-induced enhancement of 
electrical resistance.  
• The primary objective is delineate the involvement of homophilic VE-cadherin 
binding and cell spreading in the enhancement of endothelial barrier function 
induced by S1P. 
 
Study 2. To investigate S1P effects on the maintenance of endothelial barrier function 
through regulating trafficking of VE-cadherin. 
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• Hypothesis 1. S1P enhances the localization of VE-cadherin at adherens 
junctions by increasing recycling and decreasing endocytosis of VE-cadherin. By 
these processes, S1P stabilizes the localization of VE-cadherin.  
• Hypothesis 2. S1P rescues the VEGF-induced decrease in membrane VE-
cadherin by blocking the VEGF-induced β-arrestin2-related endocytosis of VE-
cadherin.  
 
Study 3. To investigate if p120 is involved in regulated VE-cadherin trafficking by S1P. 
• Hypothesis. Increased interaction of p120 with VE-cadherin by S1P facilitates 
VE-cadherin trafficking. 
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Study 1 
 
 
 
 
Sphingosine 1-phosphate rapidly increases endothelial barrier 
function independent of VE-cadherin but requires cell spreading and 
Rho kinase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: permeability, microscopy, electric cell-substrate impedance 
sensing, human umbilical endothelial cell. 
 
 14
ABSTRACT 
 
Sphingosine 1-phosphate (S1P) rapidly increases endothelial barrier function and 
induces the assembly of adherens junction proteins, VE-cadherin and catenins.  Since 
VE-cadherin contributes to the stabilization of the endothelial barrier, I determined if the 
rapid, barrier-enhancing activity of S1P requires VE-cadherin.  Ca2+-dependent, 
homophilic VE-cadherin binding of endothelial cells, derived from human umbilical veins 
and grown as monolayers, was disrupted with EGTA, an antibody to the extracellular 
domain of VE-cadherin, or gene silencing of VE-cadherin with small interfering RNA 
(siRNA).  All three protocols caused a reduction in the immunofluorescent localization of 
VE-cadherin at intercellular junctions, the separation of adjacent cells, and a decrease 
in basal, endothelial electrical resistance.  In all three conditions, S1P rapidly increased 
endothelial electrical resistance.  These findings demonstrate that S1P enhances the 
endothelial barrier independently of homophilic VE-cadherin binding.  Junctional 
localization of VE-cadherin, however, was associated with the sustained activity of S1P.  
Imaging with phase-contrast and differential interference-contrast (DIC) optics revealed 
that S1P induced cell spreading and closure of intercellular gaps.  Pretreatment with 
Latrunculin B, an inhibitor of actin polymerization, or Y-27632, a Rho kinase inhibitor, 
attenuated cell spreading and the rapid increase in electrical resistance induced by 
S1P.  I conclude that S1P rapidly closes intercellular gaps, resulting in an increased 
electrical resistance across endothelial cell monolayers, via cell spreading and Rho 
kinase and independently of VE-cadherin.  
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INTRODUCTION 
 
 Vascular endothelia act as a restrictive barrier and as such regulate many 
biological processes such as protein and fluid transport, inflammation, white cell 
emigration, and angiogenesis. Disruption of the endothelial barrier leads to 
accumulation of fluid and macromolecules in the interstitial space, resulting in edema 
and dysfunction of tissues and organs (1, 11, 14). The cellular mechanism(s) that 
regulates the endothelial barrier is not known and may involve a number of cellular 
processes.  Proposed mechanisms include alterations in the integrity of the junctions, 
the cytoskeleton, and focal adhesions and cellular retraction/contraction and relaxation 
(1, 11, 14). Tight junctions comprised of occludins, claudins, ZO-1, etc. impart the 
barrier characteristics of epithelial cells; however, their importance with respect to 
endothelial barrier function requires further study (1). The endothelial adherens junction, 
containing vascular endothelial (VE)-cadherin, other cadherins, and catenins, has been 
studied extensively, and modifications to VE-cadherin profoundly affect the integrity of 
the endothelial barrier. For example, antibodies directed toward the extracellular domain 
of VE-cadherin increased the permeability of endothelial cell monolayers (4) and the 
vascular permeability in heart and lungs of mice (5).   
 
Sphingosine 1-phosphate (S1P) is a biologically active lipid released from a 
number of cells, notably platelets, and is present in blood and serum at nanomolar to 
micromolar concentrations. S1P enhances the barrier function of cell monolayers (8), 
prevents the increase in hydraulic conductivity induced by platelet-activating factor in 
single venular microvessels (17), and attenuates the increase in pulmonary edema in 
mice and dogs subjected to intra-tracheal endotoxin (12, 19). In addition, S1P enhances 
the localization of VE-cadherin and the catenins, α, β, and γ, at endothelial junctions 
within 30 to 60 min of treatment (9, 13). S1P has also been shown to induce membrane 
ruffling and cell spreading of single endothelial cells (6, 18) and lamellipodia formation 
and cell spreading at the leading edge of wounded, endothelial cell monolayers (25). 
Cell spreading is also induced by cAMP-enhancing agents that are well known to rapidly 
tighten the endothelial barrier (15, 22).   
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Therefore, the primary objective of the study was to delineate the involvement of 
homophilic VE-cadherin binding and cell spreading in the enhancement of endothelial 
barrier function induced by S1P. VE-cadherin binding was disrupted by using three 
different methodologies, addition of EGTA to the cell culture medium to lower 
extracellular Ca2+, addition of an antibody to the extracellular domain of VE-cadherin, 
and gene silencing of VE-cadherin with small interfering RNA (siRNA).  Imaging of live 
cells by phase-contrast and differential interference-contrast (DIC) optics documented 
changes in cell shape. Evidence of closure of intercellular gaps, induced by the 
treatment of EGTA, was demonstrated microscopically and by an increase in 
endothelial electrical resistance. Since actin polymerizes at the leading edge of 
spreading cytoplasm (21), S1P reorganizes actin to the cell periphery (8), and activation 
of the small GTPase Rho has been implicated in the spreading of single endothelial cells 
by S1P (18), I further determined if inhibitors of actin polymerization and Rho kinase, an 
effector of Rho, would impede the spreading of endothelial cells by S1P. 
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MATERIALS AND METHODS 
 
Materials.  S1P was purchased from Avanti Polar Lipids (Alabaster, AL).  Gentamicin 
sulfate was from ICN Biomedicals, Inc. (Aurora, OH).  Newborn calf serum and bovine 
brain extract were from Cambrex Corporation (East Rutherford, NJ).  Prolong Gold anti-
fade reagent, Alexa Fluor-labeled secondary antibodies and Alexa Fluor-labeled 
phalloidin were from Invitrogen Molecular Probes (Eugene, OR).  Gold-coated ECIS 
(Electrode Cell-substrate Impedance Sensing) electrodes were from Applied Biophysics 
(Troy, NY).  Rabbit anti-human VE-cadherin antibodies were purchased from 
USBiological (Swampscott, MS) and Axxora (San Diego, CA).  Goat anti-human VE-
cadherin antibody and normal rabbit IgG were from Santa Cruz Biotechnology (San 
Diego, CA).  Horseradish peroxidase conjugated secondary antibodies were purchased 
from Chemicon International (Temecula, CA).  Control (scrambled) siRNA and VE-
cadherin siRNA (Smartpool) were from Dharmacon (Chicago, IL).  Nitrocellulose 
membranes and ECL (enhanced chemiluminescence) Western blotting detection 
reagents were from Amersham Biosciences (Buckinghamshire, England).  All other 
chemicals were from Sigma-Aldrich (St. Louis, MO).  
 
Cell Culture.  Endothelial cells were isolated from human umbilical veins (HUVEC) with 
1 mg/ml of type I collagenase and grown in MCDB-131 (MCDB) culture medium 
containing 5% (v/v) human serum, 20% (v/v) newborn calf serum, 7.5 μg/ml of 
endothelial cell growth supplement, 4.5 μg/ml of bovine brain extract, 25 μg/ml of 
porcine intestinal heparin, and 50 μg/ml of gentamicin sulfate.  HUVECs (passages 2-8) 
were grown to confluence (2 d) in a humidified incubator maintained at 37° C and 5% 
CO2.  Before treatment with S1P, MCDB containing 25% serum was replaced with 
serum-free MCDB, and the cells monolayers were allowed to equilibrate for 2 h in an 
incubator.   
 
Transendothelial electrical resistance.  To assess changes in endothelial barrier 
function, electrical resistance was measured continuously across HUVEC monolayers 
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by ECIS (7; 16).  Briefly, HUVECs (80,000-100,000 cells) were seeded onto ECIS 
cultureware (0.8 cm2/well) precoated with 0.2% gelatin. The measured electrical 
resistance was of those cells located on the small gold electrode (5 x 10 4 cm2) in each 
of the wells.  The culture medium was the electrolyte, and the small gold electrode, 
covered by confluent endothelial cells, and a larger gold counter-electrode (~2 cm2) 
were connected to a phase-sensitive, lock-in amplifier.  A constant current of 1 μA was 
supplied by a 1-V, 4000-Hz alternating current through a 1-MΩ resistor.  Changes in 
voltage between the small electrode and the large counter electrode were monitored by 
the lock-in amplifier, stored, and then calculated as resistance by the computer. The 
small size of the cell-seeded electrode is the critical feature of the system.  When 
electrodes of 10-3 cm2 or smaller are used, the impedance at the small electrode 
dominates the system, allowing for assessment of the morphological changes of the 
cells located at this interface.  Electrical resistance of the bare electrode is ~2,000 ohms 
and increases to 10,000 ohms or greater when HUVECs have become confluent.  If the 
electrical resistance of the endothelial cell-covered electrode is 10,000 ohms, as 
depicted in Figure 4, and is corrected for electrical resistance of the bare electrode 
(2,000 ohms), then multiplying 8,000 ohms times the electrode surface area of 5x10-4 
cm2 yields a basal electrical resistance across the HUVEC monolayer of 4 ohms•cm2, 
similar to 5 ohms•cm2 as reported using a Ussing-type recording chamber (24).    
 
EGTA Protocol (Ca2+-switch protocol).  HUVEC monolayers were treated with 2 mM 
EGTA (ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid) for 10 min to 
chelate extracellular Ca2+, followed by 1) no treatment, 2) adding 400 μl of fresh MCDB 
containing 1.6 mM Ca2+ to restore extracellular Ca2+, 3) adding only 1 μM S1P (in 1 μl) 
without restoring extracellular Ca2+), and 4) adding S1P and MCDB together.  For 
treatments 1 and 3 above, EGTA was present in the cell culture medium for the entire 
experimental period.  For treatments 2 and 4 above, culture medium was withdrawn at 
10 min after the administration of EGTA and before the addition of fresh MCDB.  S1P 
was solubilized in methanol with sonication and transferred to microcentrifuge tubes 
(0.5 ml).  Methanol was subsequently removed by nitrogen, and the tubes with S1P 
were stored at -20° C.  S1P was reconstituted in TBS for experimentation.   
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Immunofluorescence confocal microscopy.  After the various treatments, HUVECs 
monolayers were rinsed with phosphate buffered saline containing Ca2+ and Mg2+ 
(PBS+/+).  Cells were fixed with 3.7% paraformaldehyde for 15 min, permeabilized for 5 
min in cytoskeletal buffer (10 mM PIPES at pH 6.8, 3 mM MgCl2, 100 mM NaCl, and 
300 mM sucrose) containing 0.5% Triton X-100, then incubated for 20 min with 5% 
BSA.  Rabbit anti-human VE-cadherin polyclonal antibody was added to the cells for 60 
min, followed by Alexa Fluor 488- or 594-labeled goat anti-rabbit IgG and Alexa Fluor 
488-labeled phalloidin to identify actin filaments, and the cells were rinsed several times 
with PBS+/+.  Cells were mounted with Prolong Gold anti-fade reagent.  Images were 
generated by confocal laser scanning with a Zeiss LSM 510 confocal microscope.  
When comparing images, the fluorescent signals were measured at emission 
wavelengths of 488 and 594 nm with the same pinhole (less than 1 μm), the same 
detector gain, and the same amplifier offset.  
 
RNA Interference.  VE-cadherin siRNA was transiently transfected into HUVECs by 
electroporation with the Nucleofector I device (Amaxa Biosystems, Berlin, Germany).  
Briefly, 90% confluent cell monolayers were trypsinized and individual cells counted.  
After centrifugation, 1.5x106 cells were resuspended in 100 μl of a Nucleofector solution 
(7.25 mM ATP, 12 mM MgCl2⋅6H2O, 88 mM KH2PO4, 14 mM NaHCO3, and 2 mM 
glucose at pH 7.4) with 400 pmoles of VE-cadherin siRNA or control, scrambled siRNA.  
The cells in solution were transferred immediately to a cuvette and electroporated in the 
Nucleofector apparatus using the U-01 program.  Transfected cells were recovered with 
warm, fresh MCDB for 5 min, and seeded immediately on 0.2% gelatin-coated ECIS 
wells and monitored for electrical resistance or seeded on 24-well tissue culture plates 
and placed in an incubator for 2 d until used for microscopy or Western blot 
experiments.  The protein level of VE-cadherin was quantified from Western blots by 
densitometry after normalization to β-actin as a protein loading control. 
 
Immunoblotting.  Cells were washed 2x in ice-cold PBS, lysed in RIPA buffer (15 mM 
NaCl, 50 mM Tris, 1% NP-40, and 0.5% sodium deoxycholate) containing 2 mM EGTA, 
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phosphatase inhibitors (1 mM sodium vanadate and 1 mM phenylmethanesulfonyl 
fluoride), and proteinase inhibitors (5 μg/ml of aprotinin and 2 μg/ml of leupeptin).  
Samples were clarified by centrifugation at 14,000 rpm for 10 min at 4° C.  Proteins 
were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to Nitrocellulose membrane using a mini-Protean 
electrophoresis system.  Protein blots were probed with indicated primary antibodies, 
followed by the appropriate horseradish peroxidase-conjugated secondary antibody, 
and developed by enhanced chemiluminescence. 
 
Cell Spreading.  HUVECs were grown to confluence in 35-mm glass bottom culture 
dishes or Delta T culture dishes.  Cells were placed in serum-free MCDB with 20 mM 
HEPES for 2 h.  For phase-contrast microscopy, 35-mm glass bottom dishes were 
inserted into a temperature (37o C) and humidified controlled chamber mounted on the 
stage of a Zeiss AxioVert 200M microscope, and cells were viewed through a 20X 
phase-contrast objective, and 1.6X Optovart to increase magnification.  For DIC 
microscopy, Delta T culture dishes, with a temperature-controlled bottom, were placed 
on the stage of a Nikon Eclipse TE 2000-5 microscope, and cells were viewed through a 
20X DIC optical lens.  Phase-contrast images were obtained using a Zeiss AxioCam 
camera and Axiovision software, and DIC images were processed using a Nikon 
camera and Metamorph software.  
 
Statistics.  All values are presented as means ± SE.  A minimum of three experiments 
was conducted for ECIS experiments and five for microscopy experiments.  Data on 
electrical resistance were analyzed with a 2-way analysis of variance with repeated 
measures (26).  Differences between treatments at specific time points were analyzed 
further with a Bonferroni post-test.  Statistical significance was set at P<0.05. 
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RESULTS 
 
S1P rapidly increased endothelial electrical resistance independently of 
homophilic VE-cadherin binding.  S1P has been reported to increase the localization of 
VE-cadherin at intercellular junctions (9; 13).  To determine whether this increase is 
responsible for the rapid increase in endothelial electrical resistance induced by S1P,  
                    
Figure 1.  S1P rapidly increased endothelial electrical resistance after chelation of
extracellular Ca2+ with EGTA.  Ca2+ in culture media of cell monolayers, derived from human
umbilical vein endothelial cells (HUVECs), was chelated with 2 mM EGTA.  Cells were then
not treated (EGTA, open circles) or treated (arrow) with MCDB-131 (MCDB, open squares)
to restore extracellular Ca2+, S1P alone (1 μM in 1 μl, closed triangles), or S1P and MCDB
(closed circles).  EGTA-containing medium was removed before addition of MCDB without or
with S1P but remained for cell monolayers not treated or treated with S1P alone.  a)
Continuous data recorded over 180-min time period; b) values at 10 min after treatments with
MCDB, S1P, or MCDB+S1P; c) values at 140 min after treatments.  Note that S1P rapidly
increased endothelial electrical resistance (ER) without or with addition of MCDB (a,b),
whereas sustained activity of S1P required MCDB (a,c).  n=6 in each group; *P<0.05 from
EGTA; #P<0.05 from EGTA:MCDB in (b) and EGTA:S1P in (c). 
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 homophilic VE-cadherin binding was disrupted by three different protocols: 1) addition 
of 2 mM EGTA to chelate extracellular Ca2++, 2) addition to the culture medium of an 
antibody to the extracellular domain of VE-cadherin, and 3) gene silencing of VE-
cadherin.  In all three protocols, S1P (1 μM) rapidly increased electrical resistance 
 
Figure 2.  S1P enhanced the junctional localization of VE-cadherin and peripheral actin.  EGTA
protocol outlined in Figure 1 was repeated for visualization of VE-cadherin and filamentous
actin (F-actin) at cell periphery of same cells.  a,b) Representative micrographs depicted are of
HUVEC monolayers at 10 min (a) or 140 min (b) after treatment with MCDB, S1P, or S1P plus
MCDB.  In fixed and permeabilized cell monolayers, VE-cadherin was visualized by incubation
with rabbit anti-human VE-cadherin polyclonal antibody and Alexa Fluor 594-labeled goat anti-
rabbit secondary antibody, and filamentous actin was visualized with Alexa Fluor 488-labeled
phallodin.  Note that treatment with S1P plus MCDB increased presence of VE-cadherin at
intercellular junctions (a), that S1P alone and S1P plus MCDB reorganized actin to cell
periphery (a), and that presence of junctional VE-cadherin was maintained for 140 min only
after treatment with MCDB or S1P plus MCDB.  Scale bars, 10 μm. 
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across endothelial cell monolayers in association with a reduction in the localization of 
VE-cadherin at intercellular junctions.   
Addition of EGTA to the cell culture medium caused a precipitous decrease in 
endothelial electrical resistance (Fig. 1a) and a loss of VE-cadherin at intercellular 
junctions (Fig. 2a).  After 10 min of incubation with EGTA, cell monolayers were either 
not treated or treated with MCDB (containing 1.6 mM) to replenish extracellular Ca2+, 
S1P alone (1 μM in 1 μl) , or MCDB plus S1P.  Therefore, cell monolayers not treated or 
treated with S1P alone were exposed to EGTA for the entire experimental period; 
whereas, those cell monolayers treat with MCDB or S1P+MCDB were exposed to 
concentrated EGTA for only 10 min.  Endothelial electrical resistance did not change 
with no treatment and increased slightly then slowly returned to the pre-EGTA level with 
the addition of MCDB (Fig. 1a, b).  In contrast, electrical resistance increased rapidly 
within 10 min to the pre-EGTA level or above upon treatment, respectively, with S1P 
without (Fig. 1a, b) or with MCDB (Fig. 1a, b).  The identical EGTA protocol was 
repeated to visualize VE-cadherin and filamentous actin by confocal microscopy (Fig. 
2).  A characteristic of the S1P response is a reorganization of actin to the cell periphery 
(8), which was also observed in the present study within 10 min of treatment with S1P 
or S1P plus MCDB subsequent to the addition of EGTA (Fig. 2a).  In control cell 
monolayers, VE-cadherin appeared prominently at intercellular junctions.  Twenty 
minutes (also 10 min, data not shown) after EGTA treatment, there was a reduction in 
junctional VE-cadherin and an apparent increase in VE-cadherin in the cytoplasm (Fig. 
2a, EGTA:no treatment).  In addition, gaps were present between adjacent cells.  After 
replacement of extracellular Ca2+ with the addition of fresh MDCB, VE-cadherin was 
observed to some extent at intercellular junctions and there was a reduction in 
cytoplasmic VE-cadherin within 10 min (Fig. 2a).  The effect of S1P on junctional VE-
cadherin was dependent on whether MCDB was added to restore extracellular Ca2+.  
After treatment with S1P alone for 10 min, very little VE-cadherin was observed at 
intercellular junctions. Upon treatment with S1P plus MCDB, the intensity of 
immunofluorescent staining of VE-cadherin at cell borders was greater at 10 min than 
with treatment of MCDB alone and was similar to immunofluorescent staining of control 
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cell monolayers.  Both treatments, S1P alone and S1P plus MCDB, resulted in the 
closure of most of the intercellular gaps.  These microscopy and functional findings 
provide correlative evidence that S1P rapidly closes preexisting gaps between cells and 
increases endothelial electrical resistance in association with an absence of VE-
cadherin at intercellular junctions.   
 
Similar results were obtained by the addition of an antibody to the extracellular 
domain of VE-cadherin (Fig. 3) or gene silencing of VE-cadherin (Fig. 4).  Addition to 
the culture medium of an extracellular VE-cadherin antibody resulted in a decrease in 
basal, endothelial electrical resistance (Fig. 3) and a discontinuous appearance of VE-
cadherin at intercellular junctions (data not shown) as compared to the addition of 
normal rabbit immunoglobin G (IgG).  S1P rapidly and transiently increased electrical 
resistance of cell monolayers incubated with the VE-cadherin antibody as well as the 
control IgG (Fig. 3).  Transient transfection of VE-cadherin siRNA reduced the protein  
                 
Figure 3.  S1P rapidly increased endothelial electrical resistance in presence of antibody to
extracellular domain of VE-cadherin.  Homophilic VE-cadherin binding was also disrupted by
incubation with an antibody (Ab, CD144) to extracellular domain of VE-cadherin.  HUVEC
monolayers were incubated for 60 min with VE-cadherin antibody or normal rabbit
immunoglobuIin (IgG), then treated with S1P.  Note that endothelial electrical resistance
decreased after 60-min administration of VE-cadherin antibody (open bar) and that S1P
increased electrical resistance (peak response) in both treated groups (closed bars).  n=4 in
each group; *P<0.05 vs. indicated group. 
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                  Figure 4.  S1P increased endothelial electrical resistance after gene silencing of VE-cadherin.HUVEC monolayers (90% confluence) were transiently transfected by electroporation with VE-
cadherin siRNA or scrambled siRNA.  Transfected cells were seeded on 24-well culture
dishes and incubated for 2 d until used for microscopy (a,b) or Western blot (c) experiments or
seeded on ECIS wells for continuous measurement of electrical resistance (d).  a,b) VE-
cadherin was visualized at 48 h by incubation with CD144 antibody to VE-cadherin and Alexa
Fluor 594-labeled goat anti-rabbit secondary antibody.  d) Continuous measurement of
endothelial electrical resistance for ~48 h after electroporation of VE-cadherin siRNA (open
triangles) or scrambled siRNA (close circles) and after treatment with S1P (arrow); MCDB with
25% serum was replaced with serum-free MCDB at 46 h.  e) EGTA was administered for 10
min to cell monolayers already transfected with either VE-cadherin siRNA (open triangles) or
scrambled siRNA (closed circles) then treated with S1P plus MCDB (arrow).  f) Cells were
viewed directly on ECIS wells at end of experiment by incubation with rabbit anti-human VE-
cadherin polyclonal antibody and Alexa Fluor 594-labeled goat anti-rabbit secondary antibody.
Note that S1P increased endothelial electrical resistance in both transfected groups (d) and
that increased electrical resistance was maintained only in scrambled siRNA group in which
VE-cadherin was localized to cell borders (f, upper).  n=5 in each group; *P<0.05 vs. control
groups.  Scale bars, a,b = 10 μm; f = 20 μm. 
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level of VE-cadherin by ~90% (Fig. 4c) and the localization of VE-cadherin at 
intercellular junctions (Fig. 4a, scrambled siRNA, versus Fig. 4b, VE-cadherin siRNA) 
within 48 h.  As with the other two protocols, gene silencing of VE-cadherin caused a 
decrease in basal, endothelial electrical resistance (Fig. 4d), which was apparent within 
24 h, and did not affect the rapid increase in endothelial electrical resistance induced by 
S1P.   Moreover, S1P was still active in those cell monolayers exposed to a 
combinatory protocol of reduction of VE-cadherin protein by gene silencing followed by 
chelation of extracellular Ca2+ with EGTA (Fig. 4e).   
 
S1P augmented the junctional localization of VE-cadherin.  Within 10 min of 
treatment, S1P was observed to increase the localization of VE-cadherin at intercellular 
junctions (Fig. 2a).  This observation was made only when S1P was administered in the 
presence of extracellular Ca2+.  Following the administration of EGTA (Fig. 2a), more 
VE-cadherin was present at intercellular junctions with the treatment of S1P and MCDB, 
the latter to restore extracellular Ca2+, as compared to the treatment of MCDB or S1P 
alone.  This increased localization was also observed under normal, cell culture 
conditions (Fig. 6b). 
 
Sustained increase in endothelial electrical resistance induced by S1P was 
associated with localization of VE-cadherin.  Using the EGTA protocol, there was a 
sustained increase in endothelial electrical resistance (Fig. 1a,c; also Figs. 4e and 7b) 
and VE-cadherin was localized to intercellular junctions (Fig. 2b and 4f upper) at 140 
min after S1P was administered in combination with MCDB.  Endothelial electrical 
resistance was also maintained for 140 min by S1P+MCDB in cell monolayers 
transfected with a scrambled siRNA then administered EGTA (Fig. 4e); VE-cadherin 
was localized to intercellular junctions in those cell monolayers (Fig. 4f upper).  In 
contrast, treatment with S1P alone, without the addition of MCDB, induced only a 
transient increase in electrical resistance, as electrical resistance returned to the EGTA-
only treated value by 140 min (Fig. 1a,c), and at that time-point junctional localization of 
VE-cadherin was much reduced (Fig. 2b).  The activity of S1P was also transient in cell 
monolayers pretreated with the VE-cadherin antibody, which was not removed during 
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the course of the experiment (data not shown).  Furthermore, S1P activity was transient 
in those cell monolayers reduced of VE-cadherin protein by gene silencing followed by 
chelation of extracellular Ca2+ with EGTA (Fig. 4e).  Immunofluorescent staining of VE-
cadherin was much reduced at intercellular junctions at the end of the experiment in 
these cell monolayers (Fig. 4f lower).  Therefore, the sustained increase in endothelial 
electrical resistance induced by S1P, using the EGTA protocol, appears to require VE-
cadherin.  
 
S1P induced cell spreading.  Imaging of live cells with phase-contrast and DIC 
optics revealed that endothelial cells within a monolayer spread following the 
administration of S1P (Fig. 5).  Administration of EGTA for 10 min increased the 
birefringence, indicative of a change in cell shape, of the cell monolayers as viewed by 
phase-contrast optics (Fig. 5a) and caused gaps with connecting strands to form 
between cells as viewed with DIC optics (Fig. 5b).  Subsequent treatment for 10 min 
with S1P alone or in combination with MCDB resulted in cellular changes indicative of 
cell spreading, i.e. reduction of the birefringence (Figs. 5a), reduction of the connecting 
strands between cells, closure of intercellular gaps (Figs. 5b), appearance of flatter cells 
(Figs. 5b), and ridges between adjacent cells (Fig. 5b, EGTA:S1P).  Addition of MCDB 
alone to restore extracellular Ca2+ caused cell spreading and closure of intercellular 
gaps but to a much lesser extent than with S1P.  These observations implicate cell 
spreading and the resultant closure of intercellular gaps as the mechanism for the S1P-
induced rapid increase in electrical resistance of endothelial cell monolayers. 
 
Latrunculin B inhibited S1P effects on electrical resistance and cell spreading.  
S1P is known to reorganize actin filaments to the cell periphery (8). Visualization of 
actin filaments with phalloidin conjugated to Alexa Fluor 488 revealed in the present 
study that S1P also reorganized actin to the cell periphery in the presence of reduced 
VE-cadherin at intercellular junctions, resulting from administration of EGTA (Fig. 2a).  
To determine the role of actin in the barrier-enhancing activity of S1P, actin 
polymerization was blocked with Latrunculin B.  Latrunculin B binds to actin monomers  
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                 Figure 5. S1P induced cell spreading. Cell spreading and closure of intercellular gaps of HUVEC 
monolayers were visualized with phase-contrast (a) and differential interference-contrast (DIC, b) 
optics. Increased birefringence (a) and gaps (b) with connecting strands between adjacent cells 
(b) were induced by 10-min incubation with EGTA (2mM) to culture medium. HUVEC monolayers 
were then treated for 10 min with MCDB or S1P alone or S1P+MCDB. Note that S1P treated 
without or with MCDB decreased birefringence (a) and induced cells to spread, resulting in 
closure of most of the intercellular gaps (b). Same group of cells are depicted in each row in (a) 
and (b). Scale bars, a = 2 μm; b = 20 μm. 
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Figure 6.  Inhibitor of actin polymerization attenuated S1P-induced increase in endothelial
electrical resistance and cell spreading.  HUVEC monolayers were pretreated for 30 min
with Latrunculin B (Lat) to inhibit actin polymerization before treatment with S1P for 10 min.
a) Depicts peak increases in electrical resistance, as normalized to basal values (E/B).  b)
VE-cadherin and actin were visualized, respectively, by incubation with rabbit anti-human
VE-cadherin polyclonal antibody and Alexa Fluor 488-labeled goat anti-rabbit secondary
antibody and Alexa Fluor 594-labeled phalloidin.  Same group of cells are depicted in each
column in (b).  c,d) Same group of cells in each row were imaged with phase-contrast (c)
and DIC (d) optics.  EGTA was administered to disrupt homophilic VE-cadherin binding,
resulting in formation of intercellular gaps.  Note that Latrunculin B attenuated increase in
endothelial electrical resistance (a) and reorganization of filamentous actin (F-actin) to cell
periphery (b), decrease in birefringence of cell monolayers (c), and cell spreading and
closure of intercellular gaps (d) induced by S1P.  Latrunculin B did not affect S1P-induced
increase in localization of junctional VE-cadherin (b).  n= 5 in each group in (a); *P<0.05 vs.
DMSO+S1P group.  Scale bars, b = 10 μm; c = 2 μm; d = 20 μm. 
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that results in the inhibition of the actin nucleation during polymerization of actin  
filaments. Pre-treatment with Latrunculin B for 30 min attenuated the increase in 
endothelial electrical resistance (Fig. 6a) and reorganization of peripheral actin (Fig. 6b) 
but had no effect on the increase in junctional VE-cadherin induced by S1P (Fig. 6b).  
Latrunculin B also prevented cell spreading induced by S1P.  S1P reversed the EGTA-
induced increases in birefringence (Fig. 6c) and gap formation (Fig. 6d) in cell 
monolayers pretreated with the vehicle, dimethyl sulfoxide (DMSO), but not with 
Latrunculin B.    
 
Visualization of actin filaments with phalloidin conjugated to Alexa Fluor 488 
revealed in the present study that S1P also reorganized actin to the cell periphery in the 
presence of reduced VE-cadherin at intercellular junctions, resulting from administration 
of EGTA (Fig. 2a).  To determine the role of actin in the barrier-enhancing activity of 
S1P, actin polymerization was blocked with Latrunculin B. Latrunculin B binds to actin 
monomers that results in the inhibition of the actin nucleation during polymerization of 
actin filaments. Pre-treatment with Latrunculin B for 30 min attenuated the increase in 
endothelial electrical resistance (Fig. 6a) and reorganization of peripheral actin (Fig. 6b) 
but had no effect on the increase in junctional VE-cadherin induced by S1P (Fig. 6b).  
Latrunculin B also prevented cell spreading induced by S1P.  S1P reversed the EGTA-
induced increases in birefringence (Fig. 6c) and gap formation (Fig. 6d) in cell 
monolayers pretreated with the vehicle, dimethyl sulfoxide (DMSO), but not with 
Latrunculin B.  
 
Rho kinase inhibitor attenuated S1P effects on electrical resistance and cell 
spreading.  Rho kinase and its downstream effectors influence cofilin, an actin severing 
protein (8).  Inhibition of cofilin by activated Rho kinase has been proposed to be 
responsible for the reorganization of peripheral actin induced by S1P (8).  Pre-treatment 
for 30 min with 5 μM Y-27632, a pharmacological inhibitor of Rho kinase, decreased 
basal endothelial electrical resistance and significantly attenuated the rapid increase in 
electrical resistance induced by S1P when administered either under normal conditions 
(Fig. 7a) or after EGTA treatment (Fig. 7b); Y-27632 at 1 μM had no effect in either  
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Figure 7.  Inhibitor of Rho kinase attenuated S1P-induced increase in endothelial electrical
resistance and cell spreading.  HUVEC monolayers were pretreated for 30 min with Y-27632
(Y, 1 and 5 μM), an inhibitor of Rho kinase, before treatment with S1P (a,c,d), MCDB alone
(b), or S1P+MCDB (b) .  a) Depicts peak increases in electrical resistance, as normalized to
basal values (E/B).  b,c,d) EGTA was added to disrupt homophilic VE-cadherin binding and
induce formation of intercellular gaps.  Same group of cells in each row were imaged with
phase-contrast (c) or DIC (d) optics.  Note that Y-27632 at 5 μM attenuated increase in
endothelial electrical resistance (a,b), decrease in birefringence of cell monolayers (c), and
cell spreading and closure of intercellular gaps (d) induced by S1P.  Y-27632 at 1 μM had no
effect on these parameters.  n=3 in each group in (a) and n=4 in each group in (b); *P<0.05
vs. Control (Con)+S1P group (a) and Y, 1 μM+EGTA:MCDB+S1P (b).  Scale bars, c = 2 μm;
d = 20 μm. 
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condition (Fig. 7a,b).  In the EGTA protocol, addition of MCDB caused a small increase 
in endothelial electrical resistance, which slowly increased to the pre-control level (Fig. 
7b), an observation similar to that depicted in Fig. 1a.  Pre-treatment with Y-27632 
before the addition of EGTA also attenuated the decrease in birefringence, spreading of 
endothelial cells, and closure of intercellular gaps induced by S1P, as viewed by phase-
contrast (Fig. 7c) and DIC (Fig. 7d) optics.  Therefore, the findings with inhibitors of 
actin polymerizaton and Rho kinase suggest that S1P rapidly increases endothelial 
electrical resistance via an actin-dependent process that involves Rho kinase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 33
DISCUSSION 
 
Two publications have demonstrated that S1P enhances the localization of 
endothelial adherens junction proteins, VE-cadherin and catenins, within 30 to 60 min of 
treatment (9, 13).  S1P, however, rapidly increases endothelial barrier function (8, 17), 
as noted by a peak increase in electrical resistance within 6-10 min.  Whether VE-
cadherin plays a significant role in this rapid activity of S1P was an intriguing question 
especially after I observed that S1P enhanced the localization of VE-cadherin within 10 
min of treatment.  Based on experiments whereby homophilic VE-cadherin binding was 
disrupted by three different mechanisms, cell monolayers were imaged with phase-
contrast and DIC optics, and inhibitors of actin polymerization and Rho kinase were 
administered, I conclude that the rapid increase in endothelial electrical resistance 
induced by S1P occurs independently of homophilic VE-cadherin binding and requires 
cell spreading and Rho kinase.  However, our initial findings suggest that the sustained 
activity of S1P, demonstrated in the EGTA protocol, requires VE-cadherin.        
 
S1P induces the assembly of adherens junctions via activation of the small 
GTPases, Rac1 and Rho (9, 13).  Localization of VE-cadherin and the catenins, α, β, 
and γ, to intercellular junctions increased markedly and more VE-cadherin was 
demonstrated in the Triton X-100 insoluble (actin associated fraction) within 60 min in 
HUVECs treated with S1P.  Either inhibition of Rho with C3 exoenzyme or Rac1 with 
dominant-negative N17Rac1 diminished the increased immunofluorescent staining of 
VE-cadherin at intercellular junctions (9).  Similar increases in VE-cadherin and β-
catenin were also observed at intercellular junctions within 30 min of treatment of S1P 
(13).  In the present study, I observed an increased immunofluorescent localization of 
VE-cadherin at intercellular junctions within 10 min of S1P treatment.  
 
Since this 10-min time point temporally aligns with the rapid activity of S1P, I 
determined if VE-cadherin is responsible for the rapid increase in endothelial electrical 
resistance induced by S1P.  Homophilic VE-cadherin binding was disrupted by three 
different protocols, and all three protocols caused the reduction in immunofluorescent 
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localization of VE-cadherin at intercellular junctions, separation of adjacent endothelial 
cells, and a decrease in basal, endothelial electrical resistance.  The important finding 
was that S1P rapidly increased endothelial electrical resistance in all three protocols.  
Following the administration of EGTA, the rapid increase in electrical resistance 
occurred when S1P was administered either without or with restoration of extracellular 
Ca2+ with MCDB.  VE-cadherin was present at intercellular junctions in monolayers 
treated with MCDB alone and was increased with treatment of S1P plus MCDB, but 
there was much less VE-cadherin observed at intercellular junctions following treatment 
with S1P alone.  S1P was also effective in increasing endothelial electrical resistance 
after presumably interfering with homophilic VE-cadherin binding by incubation with an 
antibody to the extracellular domain of VE-cadherin or after VE-cadherin was reduced 
significantly by gene silencing.  These findings support our conclusion that S1P rapidly 
increases endothelial electrical resistance independently of homophilic VE-cadherin 
binding.                                              
 
The sustained increase in electrical resistance induced by S1P appears to 
require extracellular Ca2+ and the localization of VE-cadherin at intercellular junctions.  
Following the administration of EGTA, the increased electrical resistance induced by 
S1P was sustained in cell monolayers containing junctional VE-cadherin.  After EGTA, 
the sustained increase in electrical resistance induced by S1P required restoration of 
extracellular Ca2+ with MCDB, which was associated with the presence of VE-cadherin 
at intercellular junctions.  Similarly, S1P maintained electrical resistance in cell 
monolayers containing junctional VE-cadherin after transfection with scrambled siRNA 
and the subsequent administration of EGTA.  In contrast, treatment with S1P without 
replenishment of extracellular Ca2+ following EGTA or after reduction of VE-protein 
coupled with EGTA resulted in only a transient increase in electrical resistance, and 
junctional VE-cadherin was much reduced at the 140-min time point. 
 
I next determined if S1P induced cell spreading, because in the initial 
experiments S1P reorganized actin to the cell periphery and also appeared to reduce 
the width of intercellular gaps initially formed by EGTA.  Cell spreading is also induced 
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by cAMP-enhancing agents that are well known to rapidly tighten the endothelial barrier 
in association with reorganization of actin to the cell periphery (15, 22).  S1P has been 
shown to induce membrane ruffling and cell spreading in single endothelial cells of 
human umbilical origin and to increase cell size (6, 18).  S1P also formed lamellipodia 
and induced cell spreading of endothelial cells at the leading edge of wounded, HUVEC 
monolayers resulting in closure of the wound (25).  In the present study, I observed by 
imaging with phase-contrast and DIC optics that S1P also induces spreading of 
endothelial cells grown as confluent monolayers.  Treatment for 10 min with S1P 
without or with MCDB to restore extracellular Ca2+ caused cells to spread resulting in 
closure of intercellular gaps, initially formed by EGTA.  These observations indicate that 
the rapid increase in electrical resistance across endothelial cell monolayers induced by 
S1P occurs via cell spreading and the subsequent closure of intercellular gaps.  
Although the above-mentioned formation of lamellipodia and subsequent closure of 
wounded HUVEC monolayers implicates the process of cell spreading, the conditions 
(injury versus EGTA-induced gap formation) and the signaling pathways are different.  
Wound closure by S1P was prevented by pre-treatment with inhibitors of Src (PP2) and 
mitogen-activated protein kinase (U0126); whereas, the increased endothelial electrical 
resistance induced by S1P was not affected by PP2 or U0126 (8).  Similarly, it was 
shown previously that U0126 did not block the increase in endothelial electrical 
resistance induced by platelet-conditioned medium (7), of which S1P has been 
suggested as the barrier-enhancing factor (20). 
 
Garcia et al. (8) initially demonstrated that S1P remodeled actin to the cell 
periphery and that Latrunculin B, an inhibitor of actin polymerization, or Y-27632, an 
inhibitor of Rho kinase, attenuated the S1P-induced increase in endothelial electrical 
resistance.  I confirmed these findings and, in addition, demonstrated that S1P 
reorganized actin to the cell periphery following disruption of homophilic VE-cadherin 
binding with EGTA and that pretreatment with Latrunculin B or Y-27632 (5 μM) 
attenuated actin reorganization and the cell spreading induced by S1P.  Y-27632 also 
lowered basal, endothelial electrical resistance in HUVEC monolayers.  The 
preventative effects of Y-27632 may be explained by the ability of Rho kinase to 
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inactivate cofilin, an actin-severing protein, via the phosphorylation of LIM kinase.  
Expression of wild-type cofilin has been reported to reduce the S1P-induced increases 
in peripheral actin and in endothelial electrical resistance (8).  Rho kinase is also an 
effector for the small GTPase Rho, and activation of Rho has been implicated in the 
spreading of single endothelial cells by S1P (18) or of cells grown on type IV collagen 
(10).  In these studies, inactivation of Rho with C3 exoenzyme blocked spreading of 
endothelial cells.  The barrier-enhancing activity of S1P, therefore, appears to be 
dependent on the Rho-Rho kinase-signaling pathway. 
 
Rho kinase has also been implicated in loosening of the endothelial barrier.  Y-
27632 attenuated the activated neutrophil-induced increases in albumin permeability of 
porcine coronary venules and of cell monolayers derived from coronary venular 
endothelia and in cell tension of coronary venular endothelia (2).  A similar attenuation 
of albumin permeability by Y-27632 was demonstrated in porcine coronary venules and 
coronary venular endothelia treated with vascular endothelial growth factor (23).  
Furthermore, transfection of constitutively active Rho kinase increased the permeability 
and endothelial cell tension in these two model systems (2).  With regard to the effect of 
inhibition of Rho kinase on thrombin’s ability to increase endothelial permeability, the 
findings are equivocal.  In one study, Y-27632 prevented the increase in endothelial 
permeability (27), but not in another study (3).  Y-27632 per se enhanced the barrier 
function of cell monolayers derived from bovine pulmonary artery endothelial cells, as 
assessed by a size-selective permeability assay (3).  In contrast, I show herein that Y-
27632 decreased the endothelial barrier function of HUVEC monolayers, as assessed 
by a decrease in endothelial electrical resistance.  From the findings of the above 
studies and the present study, it is apparent that the outcome of activation of the Rho 
kinase-signaling pathway is varied.  One possibility is that the cellular targets 
downstream of Rho kinase are different for various mediators or for different cell types 
and that separate or parallel pathways differentially influence endothelial barrier 
function.   
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ABSTRACT 
 
The biologically active lipid, sphingosine 1-phosphate (S1P), induces a myriad of 
cellular events including enhancement of the endothelial barrier and an increase in 
vascular endothelial (VE) cadherin.  Based on the latter observation, I hypothesized that 
S1P affects the trafficking of VE-cadherin between cell surface and cytoplasmic 
vesicles.  Immunofluorescence microscopy and a biotinylated cell impermeable reagent 
were used to demonstrate internalized and cell surface VE-cadherin.  Endocytosis of 
VE-cadherin was induced by EGTA or VEGF. S1P decreased EGTA-induced 
endocytosis and co-localization of internalized VE-cadherin with EEA 1, a marker of 
early endosomes, and prevented and reversed the effect of VEGF.  S1P also increased 
the recovery of cell surface VE-cadherin after endocytosis by EGTA or VEGF and 
increased the co-localization of internalized VE-cadherin with Rab11, a marker of the 
recycling endosome. Bafilomycin A1, an inhibitor of recycling, and microtubule 
inhibitors, taxol and colchicine, blocked the increase in junctional VE-cadherin and the 
sustained increase in endothelial electrical resistance induced by S1P, the latter using 
the Ca2+-switch protocol.  Bafilomycin A1 also prevented the increase in recovery of cell 
surface VE-cadherin induced by S1P.  When co-treated or post-treated with VEGF, S1P 
blocked or reversed the increased interaction of VE-cadherin with β-arrestin2, an 
endocytic adapter protein. I conclude that S1P stabilizes homophilic VE-cadherin 
binding by decreasing endocytosis and increasing recycling of VE-cadherin, the latter 
requiring microtubules.    
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INTRODUCTION 
 
VE-cadherin, the major protein at endothelial adherens junctions, forms Ca2+-
dependent homophilic adhesions between cells and is vital to the integrity of the 
endothelial barrier. A blocking antibody to VE-cadherin increased the vascular 
permeability in heart and lungs of mice (8), and antibodies directed to specific domains 
of the extracellular region of VE-cadherin increased the permeability of endothelial cell 
monolayers (7, 9) and/or prevented angiogenesis (21).  Down-regulation of VE-cadherin 
initiates the transition from a normal endothelial phenotype to a mesenchymal 
phenotype as is seen in mature bovine systemic and pulmonary endothelial cells and is 
related to atherogenesis (2, 3, 13).  Induction of endocytosis of VE-cadherin by vascular 
endothelial growth factor (VEGF) has been hypothesized as the cellular mechanism for 
the VEGF-induced increase in vascular permeability (15).  Therefore, alterations in the 
level of VE-cadherin have important consequences in endothelial function and 
pathophysiology.   
 
Sphingosine 1-phosphate (S1P), released mainly from activated platelets and un-
stimulated erythrocytes, induces a myriad of cellular events, one of which is 
enhancement of the endothelial barrier (14, 27).  S1P rapidly increases endothelial 
barrier function as assessed by a peak increase in endothelial electrical resistance 
within 6-10 min of treatment (14, 45), prevents the transient increase in hydraulic 
conductivity induced by platelet-activating factor in individually perfused microvessels of 
the rat mesentery (29), and reduces the increase in pulmonary edema in mice and dogs 
subjected to intratracheal endotoxin (26, 34).  S1P also enhances the localization of VE-
cadherin at endothelial junctions and induces the assembly of endothelial adherens 
junctions within 10 min of treatment (45).  This observation of an increase in junctional 
VE-cadherin prompted us to explore the cellular mechanisms for the apparent S1P-
induced stabilization of VE-cadherin.         
 
Gene expression, decreased degradation, and or membrane stabilization could 
explain the increased junctional localization of VE-cadherin induced by S1P. Since S1P 
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increases junctional VE-cadherin within 10 min, stabilization of membrane trafficking of 
VE-cadherin appeared most likely. VE-cadherin constitutively undergoes endocytosis 
via a clathrin-dependent pathway (42) and is degraded via a lysosomal pathway (41, 
42). Furthermore, trafficking of VE-cadherin has been postulated to be involved in 
angiogenesis and regulation of endothelial barrier function (42, 43). VEGF, formerly 
known as vascular permeability factor, was recently shown to increase the endocytosis 
of VE-cadherin by a signaling pathway involving an enhanced interaction of VE-
cadherin with β-arrestin2, an endocytic adaptor protein involved in receptor 
internalization (15).  Trafficking of epithelial (E)-cadherin has been extensively studied 
by Stow and co-workers (4, 5, 19, 20). These authors demonstrated that E-cadherin 
constitutively traffics from the cell surface to endocytic vesicles and either back to the 
surface or to late endosomes to be degraded.  However, recycling of E-cadherin to the 
cell surface predominates over degradation, promoting stabilization of the barrier (4, 
20). Further, endocytosis of E-cadherin is required for signals of fibroblast growth factor 
(FGF) receptors (FGFRs) (5).   
 
In this study, I hypothesized that S1P stabilizes VE-cadherin at intercellular 
junctions by influencing the trafficking of VE-cadherin, i.e. by decreasing the 
endocytosis and increasing the recycling of VE-cadherin.  Endocytosis of VE-cadherin 
was induced by EGTA and physiologically by VEGF and assessed by 
immunofluorescence microscopy and a biotinylated impermeable reagent.  Recovery of 
cell surface VE-cadherin or recycling was assessed by the biotinylated reagent, co-
localization of VE-cadherin with Rab11, a recycling endosomal marker, and bafilomycin 
A1, an inhibitor of recycling endosomes.  The interaction of β-arrestin2 with VE-cadherin 
was identified by co-immunoprecipitation.  Because active trafficking of intracellular 
vesicles involves microtubules (22, 44), inhibitors of microtubules were used to test the 
affect of VE-cadherin trafficking induced by S1P. 
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MATERIALS AND METHODS 
 
Materials.  S1P was purchased from Avanti Polar Lipids (Alabaster, AL).  Bovine 
pulmonary artery endothelial cells were purchased from Vec Technologies, Inc. 
(Rensselaer, NY).  Gentamicin sulfate was from ICN Biomedicals, Inc. (Aurora, OH).  
Newborn calf serum and bovine brain extract were from Cambrex Corporation (East 
Rutherford, NJ).  Sulfosuccinimidyl 2-(biotinamido) ethyl-dithioproprionate (sulfo-NHS-
SS-biotin) was purchased from Pierce (Rockford, IL).  Recombinant human VEGF 165 
was purchased from R&D systems, Inc. (Minneapolis, MN).  Prolong Gold anti-fade 
reagent and Alexa Fluor-labeled secondary antibodies were from Invitrogen Molecular 
Probes (Eugene, OR).  Gold-coated electrodes for the measurement of electrical 
resistance by Electrical Cell-Substrate Impedance Sensing (ECIS) were from Applied 
Biophysics (Troy, NY).  VE-cadherin antibodies were purchased from Axxora (San 
Diego, CA) and Beckman Coulter Company (Marseille Cedex, France).  β-arrestin2 
antibody was purchased from Novus Biologicals (Littleton, CO).  β-catenin antibody was 
from BD Bioscience (San Jose, CA).  p120-catenin antibody and protein A/G beads 
were from Santa Cruz Biotechnology (San Diego, CA).  Horseradish peroxidase 
conjugated secondary antibodies were purchased from Chemicon International 
(Temecula, CA). Nitrocellulose membranes and ECL (enhanced chemiluminescence) 
Western blotting detection reagents were purchased from Amersham Biosciences 
(Buckinghamshire, England).  Bafilomycin A1 was purchased from LC Laboratories 
(Woburn, MA).  Cycloheximide was a gift from Dr. Chuan Hu. All other chemicals were 
from Sigma-Aldrich (St. Louis, MO). 
  
Cell culture.  Human umbilical vein endothelial cells (HUVEC) were isolated from fresh 
human placentas by 1 mg/ml of type I collagenase and grown in MCDB-131 (MCDB) 
culture medium containing 5% (v/v) human serum, 20% (v/v) newborn calf serum, 7.5 
μg/ml of endothelial cell growth supplement, 4.5 μg/ml of bovine brain extract, 25 μg/ml 
of porcine intestinal heparin, and 50 μg/ml of gentamicin sulfate at 37°C in 5% CO2.  
HUVECs were used between passages 2 and 8.  Before treatments or ECIS 
experiments, HUVEC monolayers were serum-starved for 2 h.  Bovine pulmonary artery 
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endothelial cells (BPAEC, passages 3-18) were cultured in MCDB medium containing 
10% fetal bovine serum and 50 μg/ml of gentamicin sulfate.  BPAEC monolayers were 
serum-starved for 4 h before treatments.  HUVECs were used for all experiments 
except for experiments with VEGF. 
 
Transendothelial electrical resistance.  Electrical resistance across HUVEC and BPAEC 
monolayers was measured continuously with ECIS to assess changes in endothelial 
barrier function.  Briefly, cells were seeded onto ECIS cultureware (0.8 cm2/well) 
precoated with 0.2% gelatin.  The measured electrical resistance was of those cells 
located on the small gold electrode (5 x 10 4 cm2) in each of the wells.  The culture 
medium was the electrolyte, and the small gold electrode, covered by confluent 
endothelial cells, and a larger gold counter-electrode (~2 cm2) were connected to a 
phase-sensitive, lock-in amplifier.  A constant current of 1 μA was supplied by a 1-V, 
4000-Hz alternating current through a 1-MΩ resistor.  The computer controlled the 
output of the amplifier and switched the measurements to different electrodes in each of 
two 8-well arrays during the course of an experiment.  Changes in voltage between the 
small electrode and the large counter electrode were monitored by the lock-in amplifier, 
stored, and then calculated as impedance by the computer.  Data are presented as 
changes in the resistive portion of electrical impedance normalized to the initial value at 
time 0. 
 
Ca2+-switch protocol.  Cell monolayers were treated with 2 mM EGTA (ethylene glycol-
bis(2-amino-ethylether)-N,N,N’,N’-tetra-acetic acid) for 10 min to chelate extracellular 
Ca2+, followed by (1) adding nothing, (2) adding fresh MCDB containing 1.6 mM Ca2+ to 
restore extracellular Ca2+, or (3) adding 1 μM S1P and fresh MCDB.   
 
Immunofluorescence microscopy.  After treatments, cell monolayers were rinsed quickly 
with phosphate-buffered saline containing Ca2+ and Mg2+ (PBS+/+).  Cells were fixed, 
permeabilized, and incubated with 5% BSA.  Cells were then incubated with primary 
antibodies, followed by Alexa Fluor-labeled secondary antibodies, and rinsed several 
times with PBS+/+.  Cells were mounted with Prolong Gold anti-fade reagent.  Images 
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were generated by confocal laser scanning with a Zeiss LSM 510 confocal microscope.  
For the same group of images, the fluorescent signals were measured at emission 
wavelengths of 488 and 594 nm with the same pinhole (less than 1 μm), the same 
detector gain, and the same amplifier offset. 
To better visualize internalized VE-cadherin, cell surface (antibody labeled) VE-
cadherin was removed with an acid wash. Briefly, BPAECs were pre-incubated for 1 h 
with serum-free MCDB containing 20 mM HEPES, a mouse anti-human VE-cadherin 
antibody (cad5; 1:50 dilution) against its extracellular domain, and 3% BSA at 4°C, 
followed by several washes in PBS+/+ to remove extra antibody, and then cultured with 
MCDB for 30 min at 37°C in 5% CO2.  After indicated treatments, BPAECS were 
separated into two groups, one group was administered a mild acid wash (PBS, pH 2.7, 
containing 25 mM glycine and 3% BSA) for 15 min at 4°C to remove cell surface bound 
antibody while retaining internalized antibody (16, 43), whereas the other group was 
washed with PBS.  The cells were then processed for immunofluorescence microscopy. 
 
Transfection.  Enhanced GFP (EGFP)-tagged Rab11 was transfected into HUVECs by 
electroporation with the Nucleofector I device (Amaxa Biosystems, Berlin, Germany).  
Briefly, 90% confluent HUVEC monolayers were trypsinized and counted.  After 
centrifugation, 1.0x106 cells were resuspended in 100 μl of Nucleofector solution (7.25 
mM ATP, 12 mM MgCl2 ⋅ 6H2O, 88 mM KH2PO4, 14 mM NaHCO3, and 2 mM glucose at 
pH 7.4) with EGFP-tagged Rab11 and transferred immediately to a cuvette and 
electroporated in the Nucleofector apparatus, using program U-001.  Transfected cells 
were recovered with fresh medium at 37°C for 5 min and seeded on gelatin-coated 
glass cover-slips. Cells were placed in a humidified environment and maintained at 
37°C and 5% CO2 for 2 d until used for experimentation.   
 
Immunoblotting.  Cells were washed 2x in ice-cold PBS, lysed in RIPA buffer (15 mM 
NaCl, 50 mM Tris, 1% NP-40, 0.5% sodium deoxycholate) containing 2 mM EGTA, 1 
mM sodium vanadate, 1 mM phenylmethanesulfonyl fluoride (PMSF), 5 μg/ml of 
aprotinin, and 2 μg/ml of leupeptin.  Samples were clarified by centrifugation at 14,000 
rpm for 10 min at 4°C. Proteins were resolved by sodium dodecyl sulfate-
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polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Nitrocellulose 
membrane using a mini-Protean electrophoresis system.  Protein blots were probed 
with indicated primary antibodies, followed by the appropriate horseradish peroxidase-
conjugated secondary antibody, and developed by enhanced chemiluminescence. 
 
Biotinylation assay for assessment of VE-cadherin trafficking.  Internalized and cell 
surface VE-cadherin were quantified by using a biotinylation assay (5, 20).  Cell surface 
proteins were covalently labeled with 1.0 mg/ml of sulfosuccinimidyl 2-(biotinamido) 
ethyl-dithioproprionate (sulfo-NHS-SS-biotin), a biotin-labeled cell impermeable reagent. 
Assessment of internalized VE-cadherin (endocytosis). Cell monolayers were 
incubated with sulfo-NHS-SS-biotin at 0°C for 1 h followed by washing with a blocking 
reagent for sulfo-NHS-SS-biotin at 4°C for 10 min to quench free sulfo-NHS-SS-biotin.  
Cells were cultured in MCDB at 37°C for 30 min and treated with S1P.  Endocytosis was 
stimulated by increasing temperature to 37°C, by lowering extracellular Ca2+ with EGTA, 
or by treatment with VEGF (15).  After endocytosis, cell monolayers were washed 2x for 
20 min each with a glutathione solution at 4°C to remove cell surface biotin.  
Internalized biotinylated proteins were protected from glutathione stripping.  Cells were 
lysed in RIPA buffer with protease inhibitors.  Equal amount of proteins was incubated 
with streptavidin beads and resolved by SDS-PAGE. Internalized, biotinylated VE-
cadherin was identified with an anti-VE-cadherin antibody to the extracellular domain. 
Assessment of cell surface VE-cadherin.  Endocytosis was induced by EGTA, 
and cells were treated with VEGF or S1P, then incubated at 0°C with the biotin-labeled 
cell impermeable reagent. Cell lysates were processed as described above and 
assessed only for cell surface, actually recovered cell surface, VE-cadherin.   
 
Co-immunoprecipitation.  Cells were lysed in RIPA buffer with phosphatase and 
protease inhibitors, and lysates were centrifuged at 14,000 rpm for 10 min at 4°C to 
clear debris.   About 2 mg of protein was incubated with a rabbit anti-human VE-
cadherin antibody for 2 h at 4°C after preclearing with 50 μl of protein A/G beads for 1 h.  
Protein A/G beads were added and incubated for additional hour to pull down antibody-
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bound proteins.  Beads were washed with RIPA buffer several times and boiled in 3x 
sample buffer.  Proteins were resolved and analyzed by Western blotting. 
 
Statistics.  All values are means ± SE.  A minimum of six experiments was conducted 
for ECIS experiments and three experiments for the biotinylation assay and microscopy.  
Data on electrical resistance were analyzed with a 2-way analysis of variance with 
repeated measures (40).  Statistical significance was set at P<0.05. 
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RESULTS 
 
S1P increased junctional localization of VE-cadherin and p120.  Within 10 min of 
treatment, 1 μM S1P increased the immunofluorescent staining of VE-cadherin and 
p120 at intercellular junctions (Fig. 1).  S1P also increased N-cadherin at intercellular 
junctions (data not shown) but did not appear to affect junctional β-catenin.  This 
increase in junctional VE-cadherin was also observed using the Ca2+-switch protocol 
(Fig. 2a), whereby Ca2+ dependent, homophilic VE-cadherin binding was disrupted with 
addition of EGTA, then restored with addition of fresh MCDB.  Administration of EGTA 
resulted in a loss of VE-cadherin at cell-cell contacts and an increase in cytoplasmic 
vesicles stained for VE-cadherin.  Upon restoration of extracellular Ca2+ with MCDB, 
VE-cadherin was present at intercellular junctions by 10 min, but to a greater extent 
when also treated with S1P+MCDB (Fig. 2a).  
 
 
 
 
 
 
 
 
 
 
 
 
                      
                
Figure 1. Sphingosine 1-phosphate (S1P) increased VE-cadherin and p120 at cell-cell 
contacts. Endothelial cell monolayers derived from human umbilical veins (HUVEC) 
and seeded on glass coverslips were treated with S1P (1 μM) for 10 min.  VE-cadherin 
was visualized by incubation with a mouse anti-human VE-cadherin primary antibody 
(Cad 5) and an Alexa Fluor 594-labeled goat anti-mouse secondary antibody.  p120 
and β-catenin were viewed, respectively, by a polyclonal or monoclonal antibody. 
Column 3 depicts the merged image of VE-cadherin and p120.  Scale bar, 20 μm. 
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Figure 2. S1P influenced trafficking of VE-cadherin. Endocytosis of VE-cadherin in HUVEC 
monolayers was induced by EGTA (2 mM, a) or by increasing temperature (e). a) VE-cadherin 
was visualized by incubation with a rabbit anti-human antibody against the extracellular domain 
followed by Alexa Fluor488-labeled secondary antibody. b) Recovery of cell surface VE-
cadherin.  HUVEC monolayers were incubated with EGTA for 10 min at 37°C to induce 
endocytosis followed by an additional 10 min of EGTA (post-treatment control group) or 
treatment with MCDB or S1P+MCDB for an additional 10 min.  Cells were then incubated at 0°C 
with cell impermeable marker, sulfo-NHS-SS-biotin, for 1 h.   Cell lysed in RIPA buffer with 
protease inhibitors, and equal amount of protein was incubated with streptavidin beads to 
complex biotin-labeled proteins.  Proteins were resolved on SDS-PAGE and VE-cadherin 
identified with a rabbit anti-human antibody against its extracellular domain. VE-cadherin in total 
cell lysate was used as loading control.  c) Cells were pre-incubated at 0°C with sulfo-NHS-SS-
biotin, administered EGTA at 37°C, then treated as described in (b).  Cell surface biotin-labeled 
proteins were removed by two, 20 min washed with glutathione at 0°C, leaving internalized 
biotinylated proteins resistant to glutathione.  Cell lysates were processed as decribed in (b).  d) 
Quantification of three immunoblots shown as ratio of individually treated group to control group.  
e) Cells were incubated at 0°C with sulfo-NHS-SS-biotin for 1 h, and then temperature was 
increased from 0°C to 37°C and treated with S1P.  Cell lysates were processed as described in 
(b). b,c,d) Note that S1P decreased endocytosis and increased recovery of VE-cadherin in 
comparison with MCDB. *P < 0.05 vs. MCDB group, #P < 0.05 vs. EGTA groups. Scale bar, 10 
µm. 
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S1P decreased endocytosis of VE-cadherin and increased recovery of cell 
surface VE-cadherin. Internalized and cell surface VE-cadherin were visualized by 
immunofluorescence microscopy and quantified by the biotinylation assay.  Addition of 
EGTA for 10 and 20 min (the latter used as the control group for post-treatments) 
induced the endocytosis of VE-cadherin (Fig. 2a, c, d).  Post-treatment with MCDB for 
10 min reduced the amount of internalized VE-cadherin.  Post-treatment with S1P 
further decreased the immunofluorescent localization of VE-cadherin in the cytoplasm 
(Fig. 2a) and significantly reduced the amount of internalized, biotin-labeled VE-
cadherin in comparison with the EGTA- and MCDB-treated groups (Fig. 2, c and d, 
internalized).  Endocytosis was also induced by increasing temperature from 0°C, 
temperature at which cell surface proteins were labeled with sulfo-NHS-SS-biotin, to 
37°C.  S1P decreased the temperature-induced endocytosis of VE-cadherin at 10 and 
30 min of treatment (Fig. 2e).  Opposite results were obtained for the recovery of cell 
surface VE-cadherin.  Administration of EGTA dramatically decreased cell surface VE-
cadherin in the initial 10-min and post-10-min treatment (Fig. 2, b and d, cell surface). 
Post-treatment for 10 min with MCDB slightly increased cell surface VE-cadherin; 
whereas, S1P significantly increased the amount of cell surface VE-cadherin as viewed 
by immunofluorescent staining (Fig. 2a) and quantification by the biotin assay (Fig. 2,b 
and d, cell surface).  Quantification of three immunoblots depicts the statistically 
significant effects of S1P on endocytosis and recovery of cell surface VE-cadherin using 
the biotinylation assay (Fig. 2d).  These results demonstrate that S1P influences VE-
cadherin trafficking.    
 
S1P decreased and reversed VEGF effects on endothelial electrical resistance, 
VE-cadherin trafficking, and interaction with β-arrestin2.  Next, it was determined if S1P 
could affect the trafficking of VE-cadherin by the physiologically relevant mediator, 
VEGF (15).  For these experiments, it was necessary to switch to BPAEC monolayers, 
because VEGF mimicked the effects of S1P on increasing endothelial electrical 
resistance and decreasing the endocytosis of VE-cadherin in HUVEC monolayers.  In 
BPAEC monolayers, S1P prevented and reversed the decrease in endothelial electrical 
resistance induced by VEGF (Fig. 3a).  The effect of VEGF on internalization of VE-
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cadherin was viewed by immunofluorescence microscopy (Fig. 3b) and quantified by 
the biotinylation assay (Figs. 3, c and d).  Immunofluorescent localization of VE-
cadherin at intercellular junctions was observed by incubation with an antibody to the N-
terminus of VE-cadherin.   VEGF decreased the junctional staining of VE-cadherin and 
increased the number of endocytic vesicles containing VE-cadherin (Fig. 3b, top row).  
Co-treatment of S1P+VEGF blocked the VEGF effect resulting in the maintenance of 
cell-surface VE-cadherin (Fig. 3b, top row).  An acid wash was applied to remove all cell 
surface antibodies enabling identification only of acid-resistant, internalized VE-cadherin 
(Fig. 3b, bottom row).  This technique revealed a lesser amount of internalized VE-
cadherin in the cell monolayers co-treated with VEGF+S1P versus treatment with VEGF 
alone.  Using the biotinylation assay, it was demonstrated that VEGF increased the 
internalization of VE-cadherin (Fig. 3, c and d, internalized) and much less biotinylated 
VE-cadherin was recovered at the cell surface (Fig. 3, c and d, cell surface).  S1P 
induced the opposite effects.  Furthermore, S1P prevented and reversed these effects 
of VEGF when co-treated or post-treated for 30 min following the initial 30-min 
treatment with VEGF. These data demonstrate that S1P can block the VEGF-induced 
endocytosis of VE-cadherin. 
 
It was previously demonstrated that the increased endocytosis of VE-cadherin 
induced by VEGF requires an enhanced interaction of β-arrestin2 with VE-cadherin 
(15).  I confirmed this finding in BPAEC monolayers and extended this finding to show 
that S1P induced the opposite effect within 30 min of treatment (Fig 3, e and f).  
Furthermore, both co-treatment and post-treatment with S1P decreased and reversed 
the VEGF-induced interaction of β-arrestin2 with VE-cadherin.  
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Figure 3. S1P decreased and reversed effects of VEGF.  Endothelial cell monolayers 
derived from bovine pulmonary arteries (BPAEC) were treated individually with S1P or 
VEGF or in combination or pretreated for 30 min with VEGF then post-treated for 30 min 
with S1P.  a) Cell monolayers (n=5) were monitored continuously for changes in endothelial 
electrical resistance.  b) Cell monolayers were pre-incubated with a monoclonal VE-
cadherin antibody (cad 5) against its extracellular domain at 4°C for 1h following treatments 
at 37°C.  Cells were either washed with mild acid to remove VE-cadherin antibody to better 
visualize internalized VE-cadherin (second row) or not washed to view cell surface and 
internalized VE-cadherin antibody, and then processed for immunofluorescent staining of 
VE-cadherin.  c) Cells were incubated with sulfo-NIH-SS-biotin for assessment of 
internalized and cell surface VE-cadherin (see Fig. 2 and Methods for details).  VE-cadherin 
in total cell lysate was used as loading control.  d) Quantification of three immunoblots 
shown as a ratio of individually treated group to control group.  e) Interaction of VE-cadherin 
with β-arrestin2.  Cell lysates were immunoprecipitated with a rabbit anti-human VE-
cadherin antibody and immunoblotted for β-arrestin2 and VE-cadherin.  (f) Quantification of 
three immunoblots as normalized to VE-cadherin blots.  Note that S1P opposed these 
effects of VEGF and also blocked and reversed effects of VEGF when co- or post-treated.  
*P < 0.05 vs. VEGF groups.  Scale bar, 10 μm. 
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S1P increased co-localization of Rab11 with VE-cadherin.  Exocytosis (or 
recycling) also contributes to trafficking.  Therefore, it was determined if VE-cadherin is 
 
associated with Rab11, a marker of recycling endosomes.  EGFP-tagged Rab11 was 
transiently transfected by electroporation into HUVECs, and cells were visualized by 
immunofluorescence microscopy during the Ca2+-switch protocol.  Figure 4 shows that 
the expressed EGFP-Rab11 distributed throughout the cell but localized primarily in an 
area that could be considered the perinuclear, recycling endosome (top row).  VE-
cadherin localized at cell junctions in the control setting and after treatment with S1P for 
 
Figure 4. S1P increased co-localization of Rab11 with VE-cadherin. Enhanced green 
fluorescent protein (EGFP) tagged Rab11, a marker of recycling endosomes, was 
transiently transfected by electroporation into HUVECs. After 48 h, endocytosis was 
induced with EGTA followed by treatment with S1P+MCDB or MCDB alone.  VE-cadherin 
was visualized by incubation with monoclonal antibody (Cad 5) and Alexa Fluor 594-
labeled secondary antibody.  Note that VE-cadherin co-localized with EGFP-Rab11 
prominently in perinuclear recycling endosome (columns 2, 3, and 5) and also co-localized 
adjacent to the plasma membrane (columns 3 and 4) after treatment with S1P. Scale bar, 
5 μm. 
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10 min (columns 1 and 4).  As expected, administration of EGTA for 10 min triggered 
the internalization of VE-cadherin, that was observed throughout the cell but 
predominantly in the perinuclear, recycling endosome where VE-cadherin was co-
localized with Rab11 (merge row, columns 2, 3 and 5).  After treatment with S1P for 5 
min, VE-cadherin remained co-localized with Rab11 in the perinuclear, recycling 
endosome but was also distributed with Rab11 adjacent to the plasma membrane 
(column 3).  Upon treatment with S1P for 10 min, less VE-cadherin was co-localized 
with Rab11 in the recycling endosome and at the cell surface, and VE-cadherin once 
again outlined the cell (column 4).  With MCDB treatment, VE-cadherin co-localized with 
Rab11 only in the perinuclear, recycling endosome (column 5). 
 
S1P increased recycling of VE-cadherin.  Dependency on a recycling pathway for 
the S1P-induced increase in junctional localization of VE-cadherin demonstrated in 
Figure 1 was further demonstrated using the recycling inhibitor, bafilomycin A1.  
Bafilomycin A1 blocks the ATP-dependent proton pump that results in the inhibition of 
acidification of endosomes (20). It has been suggested that endosome acidification 
plays a crucial role in the recycling of internalized vesicles back to the plasma 
membrane. Pre-treatment with 1 μM bafilomycin A1 for 1 h prevented the S1P-induced 
increase in junctional VE-cadherin (Fig. 5a).  Bafilomycin A1 also blocked (Fig. 5b, 
lanes 5 and 6, and c) the S1P-induced increase in biotin-labeled, cell surface VE-
cadherin at 10 and 60 min (Fig. 5 b, lanes 2 and 3, and c) as assessed by the 
biotinylation assay.  S1P also increased biotin-labeled, cell surface p120 at 10 and 60 
min (Fig. 5b, lanes 2 and 3, and d); however, bafilomycin A1 did not inhibit the S1P-
induced increase in cell surface p120 at 10 and 60 min (Fig. 5b, lanes 5 and 6, and d).  
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Figure 5.  S1P augmented recycling of VE-cadherin.  HUVEC monolayers were pretreated 
for 60 min with bafilomycin A1 (1 μM), dissolved in dimethyl sulfoxide (DMSO), to inhibit 
recycling of VE-cadherin.  Cell surface VE-cadherin was identified either by 
immunofluorescence microscopy (a) or by immunoprecipitation of biotin-labeled proteins 
with streptavidin beads and immunoblotting with VE-cadherin (b).  The latter method was 
also used to identify cell surface p120 (b). c,d) Quantification of three immunoblots of VE-
cadherin or p120.  e) HUVEC monolayers were pretreated with cycloheximide, or 
cotreated with cycloheximide and bafilomycin A1, followed by addition of S1P. Cell surface 
VE-cadherin was visualized by biotinylation. *P < 0.05 vs. DMSO control groups at the 
same time course. Scale bar, 20 μm. 
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To test whether or not the S1P-induced increase in cell surface VE-cadherin is 
related to the bio-synthesis of VE-cadherin.  HUVEC monolayers were pretreated for 2 
h with 10 μg/ml of cycloheximide, an inhibitor of protein syntheses, or co-treated with 
cycloheximide and bafilomycin A1 followed by administration of S1P for 1 h. 
Cycloheximide interferes with the translocation step in protein synthesis thus blocking 
Figure 6.  Inhibition of recycling blocked sustained activity of S1P and recovery of cell surface 
VE-cadherin.  S1P-induced recycling of VE-cadherin was highlighted using Ca2+-switch protocol.  
a) Endothelial electrical resistance was continuously recorded in HUVEC monolayers pretreated 
with DMSO or bafilomycin A1, administered EGTA, and then post-treated with S1P+MCDB.  b) 
At completion of experiment (240 min), cells seeded directly on ECIS wells were visualized for 
VE-cadherin by incubation with a rabbit anti-human VE-cadherin antibody. c) Representative 
immunoblot of cell monolayers incubated with sulfo-NHS-SS-biotin to assess cell surface VE-
cadherin without or with bafilomycin A1.  VE-cadherin in total cell lysate was used as loading 
control.  d) Quantification of four immunoblots in (c).  Note that bafilomycin A1 decreased basal, 
electrical resistance and blocked sustained increase in electrical resistance and also inhibited 
increased recovery of cell surface VE-cadherin induced by S1P.  *P < 0.05 vs. same treated 
group in DMSO control.  Scale bar, 5 μm.   
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translational elongation. Cycloheximide alone failed to block the S1P-induced increase 
in biotin-labeled, cell surface VE-cadherin (Fig. 5e). However, co-treatment with 
cycloheximide and bafilomycin A1 blocked the effect of S1P. These data indicate that 
the increase in cell surface of VE-cadherin by S1P is not due to an increase in 
biosynthesis of VE-cadherin. 
 
Further indication that S1P augmented the recycling of VE-cadherin was 
demonstrated by incorporation of bafilomycin A1 with the Ca2+-switch protocol (Fig. 6). 
Pretreatment with bafilomycin A1 decreased basal, endothelial electrical resistance, 
suggesting that constitutive recycling of VE-cadherin contributes to the maintenance of 
baseline barrier function (Fig. 6a).  Following the precipitous drop in electrical resistance 
with administration of EGTA, treatment with S1P+MCDB induced a rapid increase in 
endothelial electrical that was sustained for the 3-h duration of the experiment.  
Bafilomycin A1 blocked the sustained increase in endothelial electrical resistance (Fig. 
6a).  These results indicate that basal resistance and the sustained increase in 
endothelial electrical resistance induced by S1P were dependent on recycling.  At 
completion of the electrical resistance experiment, cells seeded on the ECIS wells were 
processed for the immunofluorescent staining of VE-cadherin.  Junctional VE-cadherin 
was present at 3h after treatment with S1P but was reduced in appearance in cell 
monolayers pretreated with bafilomycin A1 (Fig. 6b).  The biotinylation assay confirmed 
these findings (Fig. 6, c and d).  S1P increased the recovery of cell surface, biotinylated 
VE-cadherin to a greater extent than MCDB (Fig. 6c, lane 4 vs. 3, and d) following the 
initial reduction by EGTA.  And pretreatment with bafilomycin A1 blocked the S1P- as 
well as the MCDB-induced increase in biotinylated VE-cadherin at the cell surface (Fig. 
6c, lanes 5 and 6 vs. lanes 3 and 4, and d).   
 
S1P decreased EGTA-triggered endocytosis of VE-cadherin.  Trafficking of VE- 
cadherin is a dynamic process involving endocytosis and recycling, as well as 
degradation. To determine if S1P directly affected the endocytosis of VE-cadherin, 
recycling was inhibited with bafilomycin A1 and degradation was inhibited by 
chloroquine which inhibits the lysosomal pathway of protein degradation.  Before 
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labeling cell surface proteins with sulfo-NHS-SS-biotin, cell monolayers were pre-
treated for 1 h with bafilomycin A1 (1 μM) and the lysosomal inhibitor chloroquine (100 
μM).  Bafilomycin A1 caused an increase in biotinylated VE-cadherin in the cytoplasm 
(Fig. 7a, lane 2), and S1P blocked this increase (lane 3), indicating that S1P decreased 
the constitutive endocytosis of VE-cadherin.  In the presence of bafilomycin A1 and 
chloroquine, endocytosis of VE-cadherin was artificially triggered by EGTA following 
pretreatment with Tris (as vehicle control) or S1P for 30 min.  Pretreatment of S1P 
decreased the EGTA-induced endocytosis of VE-cadherin (lane 5 vs. lane 4).  The 
decrease in endocytosis by S1P was also observed with immunofluorescence 
microscopy (Fig. 7b).  Within 2 min of EGTA administration, cells were separated and 
strands extended between adjacent cells. In addition, internalized VE-cadherin localized 
predominantly to the sub-plasma membrane.  Administration of EGTA for 5 and 10 min 
facilitated the endocytotic process, and internalized VE-cadherin was distributed 
throughout the cytoplasm (Fig. 7b, top row).  Pretreatment with S1P for 30 min reduced 
the internalization of VE-cadherin by EGTA, and VE-cadherin was observed 
predominantly at intercellular junctions throughout the 2-10 min-administration of EGTA 
(Fig. 7b, bottom row).  
 
Figure 7 also demonstrates that internalized VE-cadherin resided in early 
endosomes identified with the early endosome antigen 1, EEA1.  In the control setting, 
VE-cadherin localized to intercellular junctions and EEA1 to cytoplasmic vesicles.  Upon 
administration of EGTA, VE-cadherin co-localized with EEA1 in cytoplasmic vesicles 
when cells were pretreated with the Tris vehicle (Fig. 7c, column 2, merge row).  In 
contrast, pretreatment with S1P blocked this co-localization (column 3, merge row), and 
VE-cadherin appeared prominently at intercellular junctions. 
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Figure 7. S1P decreased 
endocytosis of VE-cadherin 
and blocked increase in co-
localization of VE-cadherin 
with EEA 1.  The process of 
endocytosis was separated 
from recycling and 
degradation in HUVEC 
monolayers by using inhibitors 
of the latter two (a) and by 
pretreatment with S1P before 
induction of endocytosis by 
EGTA (a, b and c).  a) Cells 
were incubated with sulfo-
NIH-SS-biotin at 0°C for 1 h, 
and pretreated for 1 h with 
chloroquine to inhibit 
degradation and bafilomycin 
A1 to inhibit recycling. Cells 
were pretreated with S1P to 
determine its effects on 
internalization of VE-cadherin 
followed by addition of EGTA 
for 10 min to induce 
endocytosis.  b and c) Cells 
were pretreated for 30 min 
with Tris or S1P followed by 
administration of EGTA for 2, 
5, and 10 min (b) and 10 min 
only (c) to trigger endocytosis.  
VE-cadherin was visualized 
by incubation with a rabbit 
anti-human VE-cadherin 
antibody and an Alexa 
Fluor488-labeled secondary 
antibody, and EEA1 by 
incubation with a monoclonal 
EEA 1 antibody and Alexa 
Fluor594-labeled secondary 
antibody.  Scale bar (b and c), 
10 μm.  
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Microtubule inhibitors blocked S1P effects.  Microtubules provide the tracks for the 
exocytosis of endocytic vesicles (16, 44).  Thus, the involvement of microtubules was 
tested by pretreatment for 1 h with either taxol to inhibit depolymerization (taxol binds to 
β-subunit of tubulin on microtubules that locks the tubulin from disassembly) or 
colchicine to inhibit polymerization of microtubules (colchicine binds to free tubulins that 
results in blocking the nucleation of tubulins) followed by the Ca2+-switch protocol.  Both 
taxol and colchicine blocked the sustained increase in electrical resistance induced by 
S1P in a dose-dependent manner (Fig. 8, a and b).  As stated above, the sustained 
endothelial electrical resistance induced by S1P was related to the restoration of 
junctional VE-cadherin (Fig. 6b, 8c, DMSO control).  Immunofluorescent staining 
showed that the recovery of junctional VE-cadherin by S1P+MCDB, following induced 
endocytosis by EGTA, was attenuated by taxol and colchicine (Fig. 8c).  These two 
inhibitors of microtubules, however, did not prevent the EGTA-induced internalization of 
VE-cadherin.  These data demonstrate that the recycling of VE-cadherin induced by 
S1P transported via microtubules.  
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Figure 8. Microtubule inhibitors blocked effects of S1P.   HUVEC monolayers were 
subjected to the Ca2+-switch protocol and were either monitored continuously for 
endothelial electrical resistance (a) or viewed for VE-cadherin by 
immunofluorescence microscopy (b).  Cells were pretreated for 1 h with DMSO 
vehicle, or taxol or colchicine to inhibit microtubules. EGTA was added to induce 
endocytosis of VE-cadherin followed by treatment with S1P+MCDB.  a and b) 
Endothelial electrical resistance was monitored continuously.   c) VE-cadherin was 
visualized by incubation with a rabbit anti-human antibody.  Note that sustained 
increase in electrical resistance and increased recovery of junctional VE-cadherin 
induced by S1P were blocked by taxol and colchicines.  Scale bar, 20 μm. 
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DISCUSSION 
 
The objective of this study was to demonstrate the cellular mechanism(s) for the 
increase in junctional VE-cadherin induced by S1P within 10 min of treatment.  I 
determined using immunofluorescence microscopy and a quantitative biotinylation 
assay that S1P decreased the endocytosis and increased the recovery of cell surface 
VE-cadherin induced by EGTA and VEGF.  Furthermore, S1P increased the co-
localization of internalized VE-cadherin with Rab11 and blocked and reversed the 
VEGF-induced interaction of VE-cadherin with β-arrestin2.  Finally, inhibitors of the 
recycling process or microtubules blocked the S1P-induced increase in junctional 
appearance of VE-cadherin.  I conclude that S1P rapidly increases junctional VE-
cadherin by decreasing the endocytosis and increasing the recycling of VE-cadherin. 
 
Synthesis and degradation and in the case of a membrane protein such as VE-
cadherin movement in and out of the cell can determine the amount and cellular 
localization of a protein.  The increase in junctional VE-cadherin induced by S1P does 
not appear to involve synthesis because it can occur within 10 min of treatment. Further, 
inhibition of protein synthesis with cycloheximide had no effect.  Therefore, I focused on 
membrane trafficking of VE-cadherin involving the endocytosis of the protein from the 
cell surface to intracellular endosomes and recycling back to the cell surface through 
recycling endosomes.  Herein, I demonstrated that S1P opposed the effects of VEGF as 
well as EGTA on decreasing endothelial electrical resistance, reducing VE-cadherin at 
intercellular junctions, increasing the endocytosis of VE-cadherin, and increasing the 
interaction of β-arrestin2 with VE-cadherin.  Previous studies have demonstrated that 
VE-cadherin constitutively internalizes via a clathrin-dependent pathway (42). 
Trafficking of E-cadherin has been extensively studied by Stow et al. (4).  Using the 
biotinylation assay, these investigators found that 13% of cell surface E-cadherin is 
constitutively internalized and recycled back to the cell surface (20), and that this 
process is mediated by protein kinase C and Rac1 (1, 19).    Trafficking of E-cadherin 
appears to regulate cell-cell adhesion, morphogenesis and signaling downstream of the 
active fibroblast growth factor receptor 1 (1, 4, 5).  VE-cadherin also appears to 
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constitutively undergo endocytosis and recycling (43), and trafficking of VE-cadherin 
has been postulated to be involved in angiogenesis and regulation of endothelial barrier 
function (42, 43).  Endocytosis induced by VEGF has been hypothesized as the cellular 
mechanism for the permeability-increasing activity of VEGF (15).  The binding of VEGF 
to its VEGF2 receptor initiates the activation of Src leading to a sequence of events 
including activation of Vav2 (a guanosine exchange factor for the Rho family of 
GTPases), Rac1, and p21-activated kinase (PAK).   Active PAK induces the 
phosphorylation of Ser665 on VE-cadherin providing a signaling site for the interaction 
with beta-arrestin2 (endocytic adaptor protein) and allowing for subsequent 
internalization of VE-cadherin via a clathrin-dependent pathway (15, 42). Interestingly, 
S1P like VEGF activates Rac1 and PAK (14), and inhibition of Rac1 diminishes the 
immunofluorescent staining of VE-cadherin at intercellular junctions (28).   
 
Stow et al. (4, 20) showed that most of the endocytic vesicles containing E-
cadherin were recycled back to the cell membrane and were not targeted for 
degradation, and that recycling of E-cadherin to the cell surface predominated over 
degradation, promoting stabilization of the barrier.  This was evident when cells were 
treated with bafilomycin A1, an inhibitor of recycling endosomes.  Furthermore, E-
cadherin present in endocytic vesicles co-stained with rab5, a marker of early 
endosomes, but did not co-localize with the late endosomal marker rab7 (20).  Rab11 
locates at recycling endosomes and acts as an intermediate compartment for the post-
Golgi trafficking of E-cadherin (23). In the present study, S1P increased the recycling of 
internalized VE-cadherin back to the cell surface, as assessed by immunofluorescence 
microscopy and the biotinylation assay.  The recycling inhibitor, bafilomycin A1, 
prevented the S1P-induced increase in junctional VE-cadherin under normal conditions 
and during the Ca2+-switch protocol.  
 
Endocytosed vesicles first sort into early-endosomes, and then either go through 
late endosomes, lysosomes to be degraded, or transport back to cell membrane via 
recycling endosomes.  Early, recycling, and late endosomes are populated by specific 
Rab GTPases that cluster in these distinct domains with their effectors (37).  Rab 
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proteins, in their active form,  assemble with their effectors in responsible for vesicle 
budding, cytoskeletal transport, and target membrane fusion (38).  Internalized VE-
cadherin and E-cadherin co-localize with Rab5 found in early endosomes and EEA1, an 
effector of Rab5 (15, 20). But, internalized E-cadherin induced by increasing 
temperature did not localize with Rab7, a marker of late endosomes (20).  In the present 
study, VE-cadherin containing vesicles were initially localized to the subplasma 
membrane after 2 min of EGTA administration.  With longer administration of EGTA (5-
10 min), these vesicles distributed throughout the cells coinciding with EEA1.  S1P 
blocked the co-localization of internalized VE-cadherin and EEA1.  
 
Rab4 and Rab11 cluster in recycling endosomes and comprise the machinery 
that recycles proteins to the cell surface (33, 38).  Expression of a Rab11 mutant 
deficient in GTP binding significantly slowed transferrin-receptor recycling back to the 
cell membrane (30).  For β2-adrenergic receptors, Rab11 regulates recycling and 
targeting to lysosomes. Further, Rab11 acts as an intermediate compartment to 
regulate the post-Golgi trafficking and exocytosis of E-cadherin (23). Recycling 
endosomes distribute throughout the cell but also localize prominently in a cluster called 
the perinuclear recycling endosome.  Following treatment with EGTA for 10 min, 
internalized VE-cadherin was distributed throughout the cell in coincidence with 
expressed EGFP-Rab11 but was prominently clustered with EGFP-Rab11 in 
perinuclear recycling endosomes.  Within 5-min of treatment with S1P, co-localization 
was apparent at the subplasma membrane.  After 10-min of treatment, VE-cadherin 
appeared to a lesser degree in the perinuclear recycling endosome, still resided with 
Rab11 at the subplasma membrane, and reappeared at the cell periphery.  In contrast, 
internalized VE-cadherin co-localized with Rab11 only in the perinuclear recycling 
endosomes in MCDB-treated group.  These data suggest that S1P enhanced the 
recycling of VE-cadherin via the Rab11 GTPase. 
 
It was reported that S1P triggered exocytosis in bovine chromaffin cells (32), 
increased glutamate secretion in neurons (18), and also facilitated the endothelial 
exocytosis of Weibel-Palade bodies in part by activating of phospholipase C (PLC)-γ 
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pathways (25). Transportation of intracellular vesicles to cell membrane is a kind of 
exocytosis that involves the recycling process, and elevated intracellular Ca2+ level 
plays a role in exocytosis. Interestingly, S1P rapidly increases the intracellular level of 
Ca2+ in many cell types (32, 35, 46).  
 
Endocytosis, recycling, and degradation are dynamic processes making it difficult 
to separate the effects of S1P on these three processes.  The bafilomycin A1 
experiments clearly implicate recycling in the increased junctional localization of VE-
cadherin induced by S1P.  In the attempt to separate the effects of S1P on endocytosis, 
recycling and degradation were inhibited, respectively, by bafilomycin A1 and 
chloroquine.  Also, S1P was pretreated for 30 min before administration of EGTA for 2, 
5, and 10 min.  Immunofluorescence microscopy and the quantitative biotinylation assay 
demonstrated that S1P decreased the endocytosis of VE-cadherin.  I conclude that S1P 
can regulate both endocytosis and the recycling processes of VE-cadherin that result in 
the increased presence of junctional VE-cadherin and stabilization of the endothelial 
barrier.  
 
S1P was reported to increase microtubule polymerization (31). Microtubule 
cytoskeletons, together with the microtubule-based motor proteins, kinesin and dynein, 
have been shown to play important roles in membrane trafficking events involved in 
endocytosis and transcytosis (6, 22, 44). The cadherin-catenin complex and N-cadherin 
were shown to transport to the intercellular junctions along microtubule cytoskeletons 
and driven by kinesin (24, 31). To further prove that the S1P-enhanced junctional VE-
cadherin is through regulation of vesicle trafficking via microtubules, cells were treated 
with microtubules inhibitors, taxol and colchicine. Taxol and colchicine stabilize 
microtubules by inhibiting depolymerization or polymerization, respectively. Sokolova et 
al. (36) reported that depolymerization of microtubules has no effects on EGF 
internalization, and I also found that both taxol and colchicines have no influence on the 
EGTA-induced endocytosis of VE-cadherin. However, taxol and colchicine blocked the 
restoration of immunofluorescent localization of VE-cadherin at cell junctions and 
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prevented the S1P-induced maintenance of electrical resistance which is associated 
with junctional VE-cadherin, as originally demonstrated in our previous study (45). 
 
With respect to endocytosis and recovery of cell surface VE-cadherin, S1P and 
VEGF induced opposite responses.  Interestingly, when VEGF and S1P were co-treated 
or when VEGF was pretreated for 30 min followed by post-treatment for 30 min with 
S1P, the end results favored the effects of S1P.  This complementary response would 
implicate a transactivation event involving a receptor tyrosine kinase and a G-protein-
coupled receptor (GPCR).  S1P triggers intracellular signaling via binding to G-protein-
coupled receptors, i.e. Edg receptors. Likewise, VEGF up-regulates the expression of 
S1P1 receptors in bovine aortic endothelial cells, which was associated with enhanced 
intracellular signaling responses to S1P and the potentiation of S1P-mediated 
vasorelaxation (17).  Tanimoto et al. (39) reported that S1P activates not only S1P 
receptors but also activates the VEGF receptor Flk-1/KDR faster than VEGF 
stimulation. Endo et al. (12) proved that S1P induces membrane ruffling of human 
umbilical vein endothelial cells (HUVECs) via the vascular endothelial growth factor 
receptor (VEGFR), Src family tyrosine kinase(s), and the CrkII adaptor protein. Similarly 
epithelial growth factor (EGF) receptor, platelet derived growth factor (PDGF) receptor 
and insulin-like growth factor in response to activation of G-protein-coupled receptor 
(GPCR) has been reported (10, 11). VEGF binds to VEGF R2 that results in increases 
in permeability and endocytosis of VE-cadherin (15). In this paper, VEGF decreased the 
endothelial electrical resistance and increased the endocytosis of VE-cadherin, and S1P 
induced the opposite effects. In view of that, S1P protects endothelial barrier from the 
effects of VEGF via regulating VE-cadherin trafficking, and possibly involving the 
crosstalk between receptors of S1P and VEGF.  
 
Going over the main points in this paper, I demonstrated that S1P enhances the 
endothelial barrier by regulating VE-cadherin trafficking via decreases in endocytosis 
and increases in recycling of VE-cadherin. The recycling of VE-cadherin transports 
along microtubules.  
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p120 is potentially involved in the regulated VE-cadherin  
trafficking by S1P 
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ABSTRACT 
 
 My previous studies demonstrated that S1P regulates VE-cadherin trafficking by 
decreasing endocytosis and increasing recycling of VE-cadherin. However, what 
mechanisms contribute to these regulatory effects of S1P are still unclear. In this study, 
I found that under normal conditions (without EGTA), S1P increased the interaction of 
VE-cadherin with p120 and augmented the co-localization of VE-cadherin with p120 at 
cell-cell junctions; furthermore, S1P enhanced the association of p120 with biotinylated, 
cell surface VE-cadherin. After administration of EGTA to induce endocytosis of VE-
cadherin, association of p120 with VE-cadherin was increased by S1P as compared to 
the control treatment (MCDB) in HUVECs. S1P enhanced the co-localization of p120 
with Rab11, a marker of recycling endosomes, and the interaction of p120 with kinesin, 
a motor protein moving along microtubules. In contrast, VEGF, previously demonstrated 
to induce endocytosis of VE-cadherin via increased interaction of VE-cadherin with β-
arrestin2 (12), decreased the interaction of VE-cadherin with p120 in BPAEC 
monolayers. In addition, co-treatment of S1P with VEGF or post-treatment with S1P 
following pretreatment with VEGF blocked or reversed, respectively, the VEGF-induced 
effects. I conclude that the regulatory effects of S1P on VE-cadherin trafficking 
potentially occur through the increased interaction of VE-cadherin with p120, and the 
interaction of p120 with kinesin.  
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INTRODUCTION 
 
In my previous studies, I demonstrated that sphingosine 1-phosphate (S1P) 
enhances the endothelial barrier through regulation of VE-cadherin trafficking, i. e.  
decreasing endocytosis and increasing recycling of VE-cadherin. What cellular 
mechanisms contribute to this regulatory effects of S1P, however, are unclear. VE-
cadherin, a main protein of adherens junctions, stabilizes the endothelial barrier through 
homophilic binding of its extracellular region (5, 15). The cytoplasmic tail of VE-cadherin 
interacts with β-catenin and plakoglobin (γ-catenin) which bind to α-catenin. α-Catenin in 
turn directly interacts with actin filaments. This sequential linkage, however, is 
controversial as one study has reported that α-catenin does not bind simultaneously to 
actin and β-catenin (37). p120 catenin (p120) is the fourth catenin at the adherens 
junction. p120 binds to the cytoplasmic tail of VE-cadherin at the juxtamembrane 
domain and plays a crucial role to stabilize VE-cadherin.  p120 also regulates adherens 
junctions indirectly through its functional connections with Rho GTPases (2, 3, 14, 28). 
 
p120, a member of the armadillo family of proteins, consists of an NH2-terminal 
head domain, an ARM domain with 10 ARM repeats which is involved in the interaction 
of p120 with cadherin, and a short COOH-terminal domain (4, 30).  p120 was first 
described as a substrate of Src and other tyrosine kinases, but p120 is constantly found 
having multiple roles in cellular activities, well known as a stabilizer of cadherin (4, 10, 
16). Interaction of p120 with VE-cadherin regulates the expression of VE-cadherin 
which influences the regulation of the endothelial barrier. Gene silencing of p120 or 
mutation of the juxtamembrane domain on p120 binding site of VE-cadherin decreased 
the level of VE-cadherin, which was accompanied with internalization and degradation 
of VE-cadherin (17, 34, 35). Whereas increasing or overexpression of p120 enhanced 
the level of VE-caderin. Decreases in the p120 level caused a loss of barrier function, 
however, overexpression of p120 also disrupted endothelial barrier (17). Hence, p120 
plays an important role in regulating endothelial barrier function. p120 regulates not only 
VE-cadherin but also other cadherins. Gene silencing of p120 in cells expressing 
epithelial (E-), placental (P-) and neuronal (N-) cadherin induced rapid degradation of 
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each cadherin, as well as α- and β-catenin, that resulted in the loss of adherens 
junctions (10). 
 
 In addition to interacting with cadherins, p120 associates with cortactin via the 
cortactin N-terminal region to regulate lamellipodial dynamics and cell adhesion (6). 
Interestingly, Anastasiadis et al. (38) reported that p120 can traffic along microtubules 
via the direct interaction of its N-terminal region with the kinesin heavy chain. Kinesin is 
a motor protein and transports vesicles from minus end to plus end (cell membrane) 
along microtubules (21, 24, 25).  p120 recruits and interacts with kinesin, this interaction 
regulates not only localization and function of p120, but also facilitates the transport of 
cadherin-catenin complexes to intercellular junctions (8, 38).  
 
 In my second study, I demonstrated that S1P-induced recycling of VE-cadherin 
traffics along microtubules. Mary et al. (26) reported that microtubules and kinesin are 
crucial for the transport of N-cadherin to intercellular junctions. Furthermore, Paik et al. 
(29) showed that S1P induced microtubule polymerization, regulated the 
phosphorylation of N-cadherin and p120, and mediated trafficking of N-cadherin to the 
polarized plasma membrane. Here, I provide evidence that p120 potentially is involved 
in the effects of S1P on the regulation of VE-cadherin trafficking. Enhanced interaction 
of p120 with VE-cadherin by S1P in normal or Ca2+-switch experiments was 
investigated by using co-immunoprecipitation and biotinylation methods and visualized 
by confocal immunofluorescence microscopy. EGFP-tagged Rab11, a marker of the 
recycling endosome, was transfected into HUVECs to investigate the co-localization of 
p120 with recycling endosomes. The increased interaction of p120 with kinesin by S1P 
was investigated by co-immunoprecipitation. 
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MATERIALS AND METHODS 
 
Materials.  S1P was purchased from Avanti Polar Lipids (Alabaster, AL).  Bovine 
pulmonary artery endothelial cells were purchased from Vec Technologies, Inc. 
(Rensselaer, NY).  Gentamicin sulfate was from ICN Biomedicals, Inc. (Aurora, OH).  
Newborn calf serum and bovine brain extract were from Cambrex Corporation (East 
Rutherford, NJ).  Sulfosuccinimidyl 2-(biotinamido) ethyl-dithioproprionate (sulfo-NHS-
SS-biotin) was purchased from Pierce (Rockford, IL).  Recombinant human VEGF 165 
was purchased from R&D systems, Inc. (Minneapolis, MN).  Prolong Gold anti-fade 
reagent and Alexa Fluor-labeled secondary antibodies were from Invitrogen Molecular 
Probes (Eugene, OR). VE-cadherin antibodies were purchased from Axxora (San 
Diego, CA) and Beckman Coulter Company (Marseille Cedex, France). Beta-catenin 
antibody was from BD Bioscience (San Jose, CA).  p120-catenin antibody and protein 
A/G beads were from Santa Cruz Biotechnology (San Diego, CA).  Horseradish 
peroxidase conjugated secondary antibodies and mouse anti-kinesin heavy chain 
antibody (clone 2) were purchased from Chemicon International (Temecula, CA).  
Nitrocellulose membranes and ECL (enhanced chemiluminescence) Western blotting 
detection reagents were purchased from Amersham Biosciences (Buckinghamshire, 
England). EGFP-tagged Rab11 was a gift from Dr. Karen Martin. All other chemicals 
were from Sigma-Aldrich (St. Louis, MO). 
  
Cell culture.  Human umbilical vein endothelial cells (HUVEC) were isolated from fresh 
human placentas by 1 mg/ml of type I collagenase and grown in MCDB-131 (MCDB) 
culture medium containing 5% (v/v) human serum, 20% (v/v) newborn calf serum, 7.5 
μg/ml of endothelial cell growth supplement, 4.5 μg/ml of bovine brain extract, 25 μg/ml 
of porcine intestinal heparin, and 50 μg/ml of gentamicin sulfate at 37°C in 5% CO2.  
HUVECs were used between passages 2 and 8.  Before treatments, HUVEC 
monolayers were serum-starved for 2 h.  Bovine pulmonary artery endothelial cells 
(BPAEC, passages 3-18) were cultured in MCDB medium containing 10% fetal bovine 
serum and 50 μg/ml of gentamicin sulfate.  BPAEC monolayers were serum-starved for 
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4 h before treatments.  HUVECs were used for all experiments except for experiments 
with VEGF. 
 
Ca2+-switch protocol.  Cell monolayers were treated with 2 mM EGTA (ethylene glycol-
bis(2-amino-ethylether)-N,N,N’,N’-tetra-acetic acid) for 10 min to chelate extracellular 
Ca2+, followed by (1) adding nothing, (2) adding fresh MCDB containing 1.6 mM Ca2+ to 
restore extracellular Ca2+, or (3) adding 1 μM S1P and fresh MCDB.   
 
Immunofluorescence microscopy.   After treatments, cell monolayers were rinsed 
quickly with phosphate-buffered saline containing Ca2+ and Mg2+ (PBS+/+).  Cells were 
fixed, permeabilized, and incubated with 5% BSA.  Cells were then incubated with 
primary antibodies, followed by Alexa Fluor-labeled secondary antibodies, and rinsed 
several times with PBS+/+.  Cells were mounted with Prolong Gold anti-fade reagent.  
Images were generated by confocal laser scanning with a Zeiss LSM 510 confocal 
microscope.  For the same group of images, the fluorescent signals were measured at 
emission wavelengths of 488 and 594 nm with the same pinhole (less than 1 μm), the 
same detector gain, and the same amplifier offset. 
 
Transfection.  Enhanced GFP (EGFP)-tagged Rab11 was transfected into HUVECs by 
electroporation with the Nucleofector I device (Amaxa Biosystems, Berlin, Germany).  
Briefly, 90% confluent HUVEC monolayers were trypsinized and counted.  After 
centrifugation, 1.0x106 cells were resuspended in 100 μl of Nucleofector solution (7.25 
mM ATP, 12 mM MgCl2 ⋅ 6H2O, 88 mM KH2PO4, 14 mM NaHCO3, and 2 mM glucose at 
pH 7.4) with EGFP-tagged Rab11 and transferred immediately to a cuvette and 
electroporated in the Nucleofector apparatus, using program U-001.  Transfected cells 
were recovered with fresh medium at 37°C for 5 min and seeded on gelatin-coated 
glass cover-slips. Cells were placed in a humidified environment and maintained at 
37°C and 5% CO2 for 2 d until used for experimentation.   
 
Immunoblotting.  Cells were washed 2x in ice-cold PBS, lysed in RIPA buffer (15 mM 
NaCl, 50 mM Tris, 1% NP-40, 0.5% sodium deoxycholate) containing 2 mM EGTA, 1 
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mM sodium vanadate, 1 mM phenylmethanesulfonyl fluoride (PMSF), 5 μg/ml of 
aprotinin, and 2 μg/ml of leupeptin. Samples were clarified by centrifugation at 14,000 
rpm for 10 min at 4°C.  Proteins were resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Nitrocellulose 
membrane using a mini-Protean electrophoresis system.  Protein blots were probed 
with indicated primary antibodies, followed by the appropriate horseradish peroxidase-
conjugated secondary antibody, and developed by enhanced chemiluminescence. 
 
Biotinylation assay for assessment of cell surface VE-cadherin.  Cell surface VE-
cadherin and membrane protein-bound p120 were quantified by using a biotinylation 
assay (7, 22).  Cell surface proteins were covalently labeled with 1.0 mg/ml of 
sulfosuccinimidyl 2-(biotinamido) ethyl-dithioproprionate (sulfo-NHS-SS-biotin), a biotin-
labeled cell impermeable reagent. Briefly, after indicated treatments, cells were 
incubated at 0°C with the sulfo-NHS-SS-biotin for 1h, followed by washing with blocking 
buffer to quench free biotin. Cells were lysed in RIPA buffer with protease inhibitors.  
Equal amounts of proteins were incubated with streptavidin beads and resolved by 
SDS-PAGE. Biotinylated, cell surface VE-cadherin was identified with an anti-VE-
cadherin antibody to the extracellular domain. p120 immunoprecipitated in biotin was 
identified with a rabbit anti-p120 antibody.  
 
Co-immunoprecipitation.  Cells were lysed in RIPA buffer with phosphatase and 
protease inhibitors, and lysates were centrifuged at 14,000 rpm for 10 min at 4°C to 
clear debris.   About 2 mg of protein was incubated with a rabbit anti-human VE-
cadherin antibody or mouse anti-bovine kinesin heavy chain antibody for 2 h at 4°C 
after preclearing with 50 μl of protein A/G beads for 1 h.  Protein A/G beads were added 
and incubated for additional hour to pull down antibody-bound proteins.  Beads were 
washed with RIPA buffer several times and boiled in 3x sample buffer.  Proteins were 
resolved and analyzed by Western blotting. 
 
Statistics.  All values are means ± SE and were obtained in at least four separate 
experiments. 
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RESULTS 
 
S1P increased interaction of VE-cadherin with p120.  Within 10 min of treatment, 
1 μM S1P increased the co-localization of immunofluorescent staining of VE-cadherin 
and p120 at intercellular junctions (Fig. 1a). This increased association of VE-cadherin 
                      
 
Figure 1. S1P increased interaction of VE-cadherin with p120. HUVEC monolayers were
treated with 1 μM S1P, and co-localization and interaction of VE-cadherin with p120 were
determined by immunofluorescence microscopy (a), immunoprecipitation (b) and cell
surface biotinylation (c).  (a) Cells were treated with S1P for 10 mim, then stained by
mouse anti-human VE-cadherin and rabbit anti-mouse p120 antibodies. (b) Cell lysates
were immunoprecipitated with a rabbit anti-human VE-cadherin antibody against N-terminal
domain to pull down VE-cadherin-bound proteins and resolved on SDS-PAGE.  p120,
kinesin and VE-cadherin were identified by p120, VE-cadherin or mouse anti-bovine kinesin
heavy chain antibodies. (c) Cell surface proteins were incubated with sulfo-NHS-SS-biotin
at 0°C after S1P treatments, and equal amount of protein was incubated with streptavidin
beads to complex biotin-labeled proteins. VE-cadherin and p120 were identified by the
antibodies used in (b). Blot is representative of 3 separate experiments. Scale bar, 10 μm.  
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with p120 was also demonstrated by co-immunoprecipitation and biotinylation (Fig. 1b, 
c). S1P enhanced the interaction of VE-cadherin with p120 at 5 min (Fig. 1b, top 
bands). Interestingly, the interaction of VE-cadherin with kinesin did not increase until 
30 min (Fig. 1b bottom bands). S1P increased biotinylated, cell surface VE-cadherin at 
10 and 60 min (also demontrated in study 2) (Fig. 1c, top bands), and also biotinylated, 
cell surface protein-bound p120 (Fig. 2c, bottom bands). 
 
S1P enhanced the interaction of p120 with recycled VE-cadherin. Quantitative 
measurement of the interaction of cell surface protein-bound p120 with cell surface VE-
cadherin was highlighted by using the Ca2+-switch protocol. Administration of 2 mM 
EGTA decreased most of biotinylated, cell surface VE-cadherin (Fig. 2a, top 
band/second lane), but just partially decreased the level of p120 (Fig. 2a, bottom 
band/second lane). Subsequently, HUVEC monolayers were post-treated with MCDB to 
restore extracellular Ca2+ with or without S1P. Post-treatment with S1P plus MCDB 
 
Figure 2. S1P enhanced the interaction of p120 with recycled, cell surface VE-cadherin.
Interaction of p120 with recycled VE-cadherin was performed by pretreatment with 2 mM
EGTA to reduce cell surface VE-cadherin and post-treatment with or without S1P. (a) Cell
surface VE-cadherin and p120 were assessed by the biotinylation method. (b)
Quantification of four immunoblots shown as a ratio of individual band to control band. 
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recovered cell surface VE-cadherin to a greater extent than those post-treatments 
without S1P (Fig. 2a, b, top bands/bar, 4th, 6th and 8th lane/bar vs. 3rd, 5th and 7th 
lane/bar). Accompanied increase of p120 with increased recycled, cell surface VE-
cadherin was observed (Fig. 2a, b, bottom bands/bar).  In addition, the interaction of 
p120 with VE-cadherin was higher in the S1P-treated groups compared with the MCDB 
groups (Fig. 2a, b, bottom bands/bars, 4th, 6th and 8th lane/bar vs. 3rd, 5th and 7th 
lane/bar).    
 
           
Figure 3. S1P increased the co-localization of p120 with recycled VE-cadherin. HUVEC
monolayers were pretreated with 2 mM EGTA to reduce cell surface and increase
internalized VE-cadherin followed by post-treated with or without S1P. VE-cadherin was
visualized by incubation with a mouse anti-human VE-cadherin primary antibody (Cad 5)
and an Alexa Fluor 594-labeled goat anti-mouse secondary antibody. p120 was visualized
by incubation with a rabbit anti-mouse p120 antibody and an Alexa Fluor488-labeled goat
anti-rabbit secondary antibody. Note that p120 co-localized with VE-cadherin at the
peripheral region in the groups treated with S1P for 5 min, and co-localized with VE-
cadherin at both peripheral and junctional area in the groups treated with S1P for 10 min.
Scale bar, 10 μm. 
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 The increased interaction of p120 with recycled VE-cadherin by S1P was 
confirmed by immunofluorescent staining (Fig. 3). VE-cadherin co-localized with p120 at 
the intercellular junctions observed in the control setting (Fig. 3, control column). 
Administration of EGTA caused decreases in junctional VE-cadherin and p120, a 
reduction of the co-localization of VE-cadherin with p120, and induced internalization of 
VE-cadherin and p120 from the junction to cytoplasm (Fig. 3, 2nd column). p120 
disassociated from internalized VE-cadherin and did not co-localize with it (Fig. 3, 
merge row, 2nd column). However, post-treatment with S1P for 5 min facilitated the 
transport of internalized VE-cadherin and p120 to the cell peripheral area (Fig. 3, top 
and middle row, 3rd column) and increased the co-localization of p120 with VE-cadherin 
at these regions (Fig. 3, merge row, 3rd column). At 10 min, there was an obvious co-
distribution of junctional VE-cadherin and p120 (Fig. 3, 4th column). There was no co-
localization of p120 with VE-cadherin after post-treatment with MCDB for 5 min and  
limited co-localization was observed at 10 min (Fig. 3, merge row, 5th column). These 
data suggest that S1P increases the transport of VE-cadherin and p120 to adherens 
junctions. 
 
S1P increased co-localization of p120 with Rab11. To test if p120 plays a role 
during the S1P-facilitated recycling process, enhanced GFP-tagged Rab11 was 
transiently electroporated into HUVECs, and cells were visualized by confocal 
microscopy. p120 was reduced at cell junctions by administration of EGTA (Fig. 3 and 
4). Post-treatment of S1P for 5 min induced co-localization of p120 with Rab11 at the 
subplasma membrane and at the intercellular junction (Fig. 4, 3rd column). No 
interaction of p120 with Rab11 was observed in the MCDB-treated group (Fig. 4, 4th 
column). 
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S1P increased interaction of p120 with kinesin. Data in study 2 demonstrated 
that S1P facilitated recycling of VE-cadherin through microtubules (study 2, Fig. 9). 
Kinesin, a plus-end directed motor protein, facilitates transport of vesicles along 
microtubules (24, 25). Interestingly, p120 was reported to associate with kinesin and 
facilitate transport of cadherin-catenin complexes to intercellular junctions (8). Herein, I 
tested how p120 is involved in the effects of S1P to facilitate the transport of VE-
cadherin. The Ca2+-switch protocol was applied to induce endocytosis of VE-cadherin 
followed by post-treatment with or without S1P to restore cell surface VE-cadherin. The 
             
Figure 4. S1P increased co-localization of p120 with Rab11. EGFP-tagged Rab11 was
transiently transfected into HUVECs by electroporation. After 48 h, cell monolayers were
treated with or without S1P following pretreatment with EGTA. p120 was visualized by
incubation with a rabbit anti-mouse p120 antibody and an Alexa Fluor 594-labeled goat anti-
rabbit secondary antibody. Note that p120 co-localized with Rab11 at the peripheral area
within 5 min in S1P treated group. Scale bar, 5 μm. 
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interaction of p120 with kinesin was assessed by co-immunoprecipitation. Post-
treatment with S1P dramatically enhanced the interaction of p120 with kinesin within 5 
and 10 min of treatment compared to post-treatment with MCDB alone (Fig. 5). 
Together the data in Figures 2 and 3 suggest that S1P increases recycling of VE-
cadherin back to cell surface by increasing the interaction of recycling VE-cadherin with 
p120 and recruiting kinesin to the complex and facilitating recycling of VE-cadherin. 
 
 
S1P inhibited and reversed decreased interaction of VE-cadherin with p120 by 
VEGF. Since EGTA, used to induce endocytosis of VE-cadherin, is not a physiological 
reagent, I next studied the effects of S1P on the interaction of VE-cadherin with p120 in 
BPAEC monolayers using the physiological mediator VEGF.  VEGF decreased the 
interaction of VE-cadherin with p120 in a time-dependent manner (Fig. 6, lane 2 and 3), 
but S1P increased this interaction in the same temperal manner (Fig. 6, lane 4 and 5). 
Furthermore, co-treatment of S1P with VEGF and post-treatment with S1P after pre-
treatment with VEGF for 30 min blocked and reversed, respectively, the VEGF-induced 
decrease in interaction of VE-cadherin with p120 (lane 6 and 7). These data suggest 
             
        
Figure 5. S1P increased interaction of p120 with kinesin. HUVEC monolayers were post-
treated with or without S1P for 5, 10 and 30 min following pretreatment with EGTA. Cell
lysates were incubated with a mouse anti-bovine kinesin heavy chain antibody (clone 2) to
complex kinesin-bound proteins and immunoblotted for p120 and kinesin. Blot is
representative of 4 separate experiments. Note that S1P increased interaction of p120 with
kinesin compared to MCDB group. 
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that the cellular mechanism of S1P protection from the vascular barrier effects of VEGF 
may occur through regulation of the interaction of p120 with VE-cadherin.  
 
 
 
 
 
 
 
 
 
                     
Figure 6. S1P inhibited and reversed decreased interaction of VE-cadherin with p120
by VEGF. Endothelial cell monolayers derived from bovine pulmonary arteries
(BPAEC) were treated individually with S1P or VEGF or in combination or pretreated
for 30 min with VEGF then post-treated for 30 min with S1P. Cell lysates were
immunoprecipitated with a rabbit anti-human VE-cadherin antibody and
immunoblotted for p120 and VE-cadherin.  Note that VEGF decreased the interaction
of VE-cadherin with p120, S1P increased it and co-treatment or post-treatment with
S1P blocked and reversed VEGF effects. Blot is representative of 3 separate
experiments. 
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DISCUSSION 
 
 In this study, the role of p120 in the S1P effects on regulation of VE-cadherin 
trafficking were investigated. Xiao et al. (10, 34-36) reported that p120 is crucial for 
regulating expression and trafficking of VE-cadherin. Paik et al. (29) showed that p120 
was involved in N-cadherin trafficking mediated by S1P. Here, I demonstrated that S1P 
increased co-localization and interaction of p120 with VE-cadherin in whole cell lysate 
and at the cell surface. EGTA or VEGF were applied to highlight the study of S1P 
effects on the trafficking of VE-cadherin. S1P increased recycling of VE-cadherin to a 
greater extent and faster than MCDB (also demonstrated in study 2), and this increase 
was accompanied with an increased interaction and co-localization of p120 with 
recycled, cell surface VE-cadherin, as well as with Rab11. Interestingly, S1P also 
enhanced the interaction of p120 with kinesin. Furthermore, S1P blocked and reversed 
the VEGF-induced decrease in interaction of VE-cadherin with p120. I conclude that 
S1P increases VE-cadherin trafficking through enhanced interaction of p120 with VE-
cadherin and with kinesin to facilitate this transport. 
 
Interaction of p120 with VE-cadherin is important for maintenance of endothelial 
barrier function (17), and this is a dual interactions: one, p120 interacts with cell surface 
VE-cadherin to stabilize junctional VE-cadherin; two, p120 interacts with recycled VE-
cadherin in the cytoplasm. In the first case, Xiao et al. (35, 36) reported that p120 works 
as a cap to interact with the cytoplasmic tail of VE-cadherin and inhibits the endocytosis 
of VE-cadherin. I found that S1P increased the association of p120 with cell surface VE-
cadherin and inhibited the dynamic endocytosis of VE-cadherin (demonstrated in study 
2). Hence, during the normal situation, S1P enhances junctional VE-cadherin via an 
increase in the interaction of p120 with cell surface VE-cadherin. However, it is unclear 
if p120 also interacts with internalized VE-cadherin, I did not see any co-localization of 
p120 with cytoplasmic VE-cadherin in the control group (Fig. 1a), but this may be due to 
the small amount of VE-cadherin that dynamically internalizes. Interestingly, p120 was 
reported to facilitate transport of itself and cadherin-catenin complex to cell-cell 
junctions (8, 38), so the interaction of cytosolic p120 with recycling cadherin may 
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influence the recycling process. EGTA or VEGF was added to augment the 
internalization of VE-cadherin. During the initial endocytosis process, p120 
disassociated from internalized VE-cadherin and no-co-localization was observed as 
previously reported by Xiao et al. (35). When S1P was added to launch the recycling 
process of VE-cadherin (demonstrated in study 2), p120 interacted primarily with 
recycled VE-cadherin  and coincidently with Rab11, a marker and pivotal protein of 
recycling endosomes. p120 also interacted with cell surface VE-cadherin following the 
recovery process.  So far, the role of the small GTPase, Rab11, in the transport of VE-
cadherin facilitated by p120 is not characterized.  In summary, S1P facilitated the 
recycling of VE-cadherin possibly through an enhanced interaction of p120 with 
recycled cell surface VE-cadherin. 
 
The role of p120 in S1P effects may also involve the Rho family of GTPases.  
Rho family GTPases, such as Rac1, RhoA and Cdc42 are important for regulation of 
the endothelial barrier, actin cytoskeleton, cell spreading and migration, as well as 
cadherin trafficking (1, 18-20, 31-33). S1P activates Rac1, Cdc42, as well as RhoA and 
remodels the actin cytoskeleton (9, 13, 23, 27). p120 was reported to bind to the Rho 
family exchange factor Vav2 to activate Rac and Cdc42 (28) and even directly to Rho A 
through its Arm domain (11). Therefore, the sequence and linkage among S1P, Rho 
family GTPases and p120 with regard to VE-cadherin trafficking need further 
investigation. 
 
Interaction of β-arrestin2 with VE-cadherin triggers internalization of VE-cadherin. 
VEGF was reported to induce endocytosis of VE-cadherin through a β-arrestin2-
dependent pathway (12). In study 2, I found that S1P had the opposite effect. S1P 
suppressed and reversed the VEGF-induced interaction of VE-cadherin with β-arrestin2. 
Moreover, the present study identified that VEGF decreased the interaction of p120 with 
VE-cadherin. In contrast, S1P increased this interaction and co-treatment or post-
treatment with S1P suppressed or reversed the VEGF effects. β-arrestin2 binds to a 
conserved, phosphorylated Ser-Val-Arg (SVR) motif on the intracellular domain of VE-
cadherin where the SVR motif is just adjacent to the p120 binding region (12). The 
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increased interaction of p120 with VE-cadherin by S1P may cap the intracellular domain 
of VE-cadherin and inhibit the binding of β-arrestin2 to VE-cadherin. S1P may also 
regulate the phosphorylation level of the SVR motif, which in turn blocks VE-cadherin 
endocytosis. All of these hypotheses need to be studied in the future. 
 
Microtubules together with kinesin play a crucial role in the transport of N-
cadherin to cell-cell junctions (26, 29). p120 can directly associate with kinesin and 
microtubules (11).  The interaction of p120 with kinesin facilitates the transport of p120 
and the cadherin-catenin complex (8, 38). In study 2, I demonstrated that S1P regulated 
VE-cadherin trafficking via microtubules (study 2, Fig. 8). The present study revealed 
that S1P increased the interaction of p120 with kinesin and with VE-cadherin. However, 
it is unclear whether or not VE-cadherin can directly bind to kinesin or bind through 
p120 because kinesin was pulled down by immunoprecipitation with the VE-cadherin 
antibody not by a p120 antibody. Thus, p120 may work as a scaffold to link VE-cadherin 
and kinesin. Interestingly during normal conditions, S1P increased the interaction of 
p120 with kinesin (through immunoprecipitation of VE-cadherin) within 30 min of 
treatment. But during the recycling process induced by EGTA, this increased interaction 
by S1P occurred as early as 5 min. These data provide evidence to support that S1P 
has a dual role in VE-cadherin trafficking: one is inhibition of endocytosis; another is the 
enhancement of recycling. p120 may be involved in both processes.     
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